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Aims: To gain insight on the immunological processes behind cow’s milk allergy (CMA) and 
the development of oral tolerance. To furthermore investigate the associations of HLA II and 
filaggrin genotypes with humoral responses to early oral antigens. 
Methods: The study population was from a cohort of 6209 healthy, full-term infants who in a 
double-blind randomized trial received supplementary feeding at maternity hospitals (mean 
duration 4 days): cow’s milk (CM) formula, extensively hydrolyzed whey formula or donor 
breast milk. Infants who developed CM associated symptoms that subsided during elimination 
diet (n=223) underwent an open oral CM challenge (at mean age 7 months). The challenge was 
negative in 112, and in 111 it confirmed CMA, which was IgE-mediated in 83. Patients with 
CMA were followed until recovery, and 94 of them participated in a follow-up study at age 8-9 
years. We investigated serum samples at diagnosis (mean age 7 months, n=111), one year later 
(19 months, n=101) and at follow-up (8.6 years, n=85).  At follow-up, also 76 children 
randomly selected from the original cohort and without CM associated symptoms were 
included. We measured CM specific IgE levels with UniCAP (Phadia, Uppsala, Sweden), and 
β-lactoglobulin, α-casein and ovalbumin specific IgA, IgG1, IgG4 and IgG levels with enzyme-
linked immunosorbent assay in sera. We applied a microarray based immunoassay to measure 
the binding of IgE, IgG4 and IgA serum antibodies to sequential epitopes derived from five 
major CM proteins at the three time points in 11 patients with active IgE-mediated CMA at 
age 8-9 years and in 12 patients who had recovered from IgE-mediated CMA by age 3 years. 
We used bioinformatic methods to analyze the microarray data. We studied T cell expression 
profile in peripheral blood mononuclear cell (PBMC) samples from 57 children aged 5-12 years 
(median 8.3):  16 with active CMA, 20 who had recovered from CMA by age 3 years, 21 non-
atopic control subjects.  Following in vitro β-lactoglobulin stimulation, we measured the mRNA 
expression in PBMCs of 12 T-cell markers (T-bet, GATA-3, IFN-γ, CTLA4, IL-10, IL-16, 
TGF-β, FOXP3, Nfat-C2, TIM3, TIM4, STIM-1) with real time polymerase chain reaction, 
and the protein expression of CD4, CD25, CD127, FoxP3 with fluorescence-activated cell 
sorting. To optimally distinguish the three study groups, we performed artificial neural 
networks with exhaustive search for all marker combinations. For genetic associations with 
specific humoral responses, we analyzed 14 HLA class II haplotypes, the PTPN22 1858 SNP 
(R620W allele) and 5 known filaggrin null mutations from blood samples of 87 patients with 
CMA and 76 control subjects (age 8.0-9.3 years). 
Results:  High IgG and IgG4 levels to β-lactoglobulin and α-casein were associated with the 
HLA (DR15)-DQB1*0602 haplotype in patients with CMA, but not in control subjects. 
Conversely, (DR1/10)-DQB1*0501 was associated with lower IgG and IgG4 levels to these 
CM antigens, and to ovalbumin, most significantly among control subjects. Infants with IgE-
mediated CMA had lower β -lactoglobulin and α-casein specific IgG1, IgG4 and IgG levels 





CMA persisted beyond age 8 years, CM specific IgE levels were higher at all three time points 
investigated and IgE epitope binding pattern remained stable (p<0.001) compared with 
recovery from CMA by age 3 years.  Patients with persisting CMA at 8-9 years had lower 
serum IgA levels to β-lactoglobulin at diagnosis (p=0.01), and lower IgG4 levels to β-
lactoglobulin (p=0.04) and α-casein (p=0.05) at follow-up compared with patients who 
recovered by age 3 years.  In early recovery, signal of IgG4 epitope binding increased while 
that of IgE decreased over time, and binding patterns of IgE and IgG4 overlapped.  In T cell 
expression profile in response to β –lactoglobulin, the combination of markers FoxP3, Nfat-
C2, IL-16, GATA-3 distinguished patients with persisting CMA most accurately from patients 
who had become tolerant and from non-atopic subjects. FoxP3 expression at both RNA and 
protein level was higher in children with CMA compared with non-atopic children.  
Conclusions: Genetic factors (the HLA II genotype) are associated with humoral responses to 
early food allergens.  High CM specific IgE levels predict persistence of CMA. Development 
of tolerance is associated with higher specific IgA and IgG4 levels and lower specific IgE 
levels, with decreased CM epitope binding by IgE and concurrent increase in corresponding 
epitope binding by IgG4.  Both Th2 and Treg pathways are activated upon CM antigen 
stimulation in patients with CMA. In the clinical management of CMA, HLA II or filaggrin 
genotyping are not applicable, whereas the measurement of CM specific antibodies may assist 
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Review of the literature 
 
Introduction to cow’s milk allergy 
 
In Western societies, the earliest antigen infants are orally exposed to is commonly cow’s milk 
(CM). It elicits an immunological response which in the vast majority of infants leads to 
tolerance (Tainio et al. 1988, Kemeny et al. 1991). However, usually during the first year of life, 
2-3% of children develop cow’s milk allergy (CMA) (Host, Halken 1990, Saarinen et al. 1999). 
CMA is an adverse clinical reaction to ingested CM proteins based on an immunological 
reaction to the provoking proteins (Sicherer, Sampson 2008). The only therapy currently 
established is an elimination diet until tolerance develops, and reactive treatment of allergic 
symptoms with antihistamines, locally or systemically administered corticosteroids and/or 
injectable epinephrine in case of CM ingestion (Sicherer, Sampson 2008).  
 
Oral tolerance and cow’s milk allergy 
 
Oral tolerance can be defined as the antigen-specific suppression of cellular and/or humoral 
immune responses following preceding oral exposure to the antigen (Faria, Weiner 2005). How 
and why CMA develops instead of physiological oral tolerance, is not fully understood. Both 
genetic predisposition and environmental factors have an impact (Sicherer, Sampson 2008). 
Gut barrier, or its insufficient function, plays a central role in oral tolerance (Sampson 1999, 
Chehade, Mayer 2005). A controlled inflammation may be a central feature of the development 
of oral tolerance (Mayer et al. 2001). 
 
The gut is the largest immunological organ of the body, and most of the time it appropriately 
responds to pathogens, tolerates harmless environmental antigens (such as food proteins and 
peptides) and maintains commensal bacterial flora (Sicherer, Sampson 2008, Mowat 2003, 
Tsuji, Kosaka 2008). Exposure to foreign antigens is required for the development of the 
immune system in the gut (Menezes et al. 2003, Bouskra et al. 2008). The gut barrier consists 
of numerous components (Sampson 1999). Digestion is initiated already in the mouth by 
salivary amylases, proceeds further by gastric acid and pepsins, then in the intestine by 
pancreatic and intestinal enzymes, and finally on the gut surface by intestinal epithelial cell 
lysozyme activity (Sampson 1999). Digestion breaks proteins down into aminoacids and 
peptides of various lengths, which are less immunogenic compared with entire proteins that 
retain both sequential and conformational epitopes (Vickery, Burks 2009). One difference 
between food allergens and non-allergens is indeed the resistance to digestion (Astwood, Leach 
& Fuchs 1996). The penetration of ingested antigens is hampered by epithelial cells, the 





enterocytes (Sampson 1999, DeMeo et al. 2002).  Ingested antigens can also be blocked from 
penetration by antigen-specific secretory IgA antibodies (DeMeo et al. 2002, Kuitunen, 
Savilahti & Sarnesto 1994a, Cerutti 2008). If digested by enterocytes, peptides and aminoacids 
are further digested, and transported as aminoacids to portal circulations.  A small proportion 
(0.001-1%) of intact proteins or large, still antigenic peptides come into contact with dendritic 
cells beneath the intestinal epithelium, and are transported to the lamina propria of the 
intestine (Strobel, Mowat 1998). Increased gut permeability may disrupt the achievement of 
oral tolerance due to increased antigen load (Berin, Shreffler 2008). The gut barrier is immature 
during neonatal period, and permeability to macromolecules is higher than that of a mature gut 
(DeMeo et al. 2002, Kuitunen, Savilahti & Sarnesto 1994a, Kuitunen, Savilahti & Sarnesto 
1994b). On the other hand, an immature gut and greater permeability, may result in antigen 
exposure high enough to elicit anergy and diminished immunological responses (Schwartz 
2003, Siltanen et al. 2002). The dose of antigen exposure may also affect Th1/Th2-balance: 
large doses would promote Th1 responses and small doses Th2 responses (Rogers, Croft 1999, 
Kay 2001a). T regulatory cell function and thus tolerance may be induced by even smaller 
doses of antigens (Kretschmer et al. 2005). 
 
The gut associated lymphoid tissue (GALT) is where initiative immune responses 
predominantly take place (Mowat 2003, Cheroutre, Madakamutil 2004). Both innate and 
adaptive immune cells are active components of GALT (Cheroutre, Madakamutil 2004). 
Especially important is an area of specialized, single layer epithelium overlying lymphoid 
follicles called follicle-associated epithelium (FAE) (Mowat 2003), where the microfold (M) 
cells sample luminal antigens (DeMeo et al. 2002). These specialized M cells internalize and 
process macromolecules, which subsequently are transported to the cell surface for antigen 
presentation (Mowat 2003, DeMeo et al. 2002). Antigen sampling can also occur by two 
alternative means: dendritic cells can extend their processes to the gut lumen through the 
epithelium, or epithelial cells may transport antigens to the lamina propria (Vickery, Burks 
2009, Berin, Shreffler 2008, Cheroutre, Madakamutil 2004). Antigen sampling has been 
proposed to be a key decisive point in whether oral tolerance is induced successfully (Mayer et 
al. 2001).  
 
Dendritic cells are concentrated right under FAE (Mowat 2003). Antigen presentation by 
dendritic cells importantly controls tolerance induction in T cells (Akbari, DeKruyff & Umetsu 
2001, Coombes et al. 2007, Sun et al. 2007, Coombes, Powrie 2008). It predominantly takes 
place in Peyer’s patches, which are located beneath FAE and essential, if not required, for oral 
tolerance to proteins (Fujihashi et al. 2001, Spahn et al. 2001).  In addition, epithelial cells may 
function as antigen presenting cells particularly in maintaining local tolerance to antigens 
(Mowat 2003), and intraepithelial lymphocytes complement the function of those residing in 
GALT . Retinoic acid acting in concert with TGF-β induces tolerogenic dendritic cells and 
subsequently the generation of Tregs as well as class switching to IgA (Coombes et al. 2007, 






Following antigen presentation and costimulatory signals, lymphocytes proliferate and 
differentiate to immunocompetent cells in secondary lymphoid organs (Cheroutre, 
Madakamutil 2004, Salmi, Jalkanen 1999). They can then migrate to the effector sites lamina 
propria and intraepithelial regions (DeMeo et al. 2002, Cheroutre, Madakamutil 2004). 
Alternatively, they can reside in mesenteric lymph nodes, superior mesenteric duct, and along 
the thoracic duct (DeMeo et al. 2002). Furthermore, some enter the systemic circulation and 
migrate to other mucosal surfaces and organs (DeMeo et al. 2002, Eigenmann 2002b). The 
trafficking of naive lymphocytes to the gut and later antigen-primed memory lymphocytes 
returning from circulation to the gut are directed by the expression of gut-specific adhesion 
molecules (such as α4-integrins) as well as local secretion of various chemokines such as TNF-
α and IL-8 (Salmi, Jalkanen 1999, Eigenmann 2002b, Denning, Kim & Kronenberg 2005). The 
expression of CLA (cutaneous lymphocyte-associated antigen), a skin-specific adhesion 
molecule, in food-antigen primed T memory cells may partly explain the high prevalence of 
atopic dermatitis in food allergy (Eigenmann 2002b).  
  
High antigen exposure results predominantly in T cell anergy (Schwartz 2003, Friedman, 
Weiner 1994, Powell 2006), but may also induce a switch of Th1 and Th2 cells into IL-10 
secreting T regulatory type 1 cells (Tr1) (Meiler et al. 2008b). Low doses of antigen usually 
activate other types of T regulatory cells (Tregs) (Chehade, Mayer 2005, Sun et al. 2006). The 
de novo generation of Tregs in GALT is a crucial element of oral tolerance (Sun et al. 2007). 
Although food antigen specific Tregs are induced and reside in the gut, they also circulate in 
the body, especially at allergen exposure, to maintain systemic tolerance (Tsuji, Kosaka 2008). 
 
During pregnancy, the maternal immune system is Th2-skewed, which diminishes the risk of 
Th1-mediated rejection of the placenta (Holt, Jones 2000). Transplacental priming of the fetal 
immune system to environmental antigens results in Th2-deviation (Prescott et al. 1998). The 
immune system continues to be Th2-dominated and promote IgE production during infancy 
(Holt, Jones 2000, Prescott et al. 1998). Influenced by genetic and environmental factors, some 
infants fail to develop a Th1/Th2 balance (Prescott, Sly & Holt 1998, Prescott et al. 1998, 
Prescott et al. 1999, Neaville et al. 2003), although adequate boost towards Th1 responses may 
correct the balance with age (Holt et al. 2000). They may further mount an exaggerated Th2-
dominated response to an innocuous environmental antigen combined with impaired Th1 
responses, which leads to allergy (Kay 2001a, Holt, Jones 2000, van der Velden et al. 2001, 
Romagnani 2004, Dunstan et al. 2005). The underlying phenomenon is that the balance of 
transcriptional networks that determine T cell commitment deviates towards Th2 
differentiation (Chatila et al. 2008). Environmental factors, such as the gut commensal flora, 
influence this balance in particular via mechanisms of innate immunity (Chatila et al. 2008, 
Nigo et al. 2006, Conroy, Shi & Walker 2009). Of note, Macaubas et al reported that higher IL-
4 and IFN-γ levels in cord blood were associated with reduced risk of asthma and atopy at the 
age of six years, which may reflect the failure of transplacental interface to promote the 
maturation of fetal immune system rather than contradict with the Th1/Th2 imbalance 






Dendritic cells trigger the Th2 differentiation by antigen presentation, co-stimulatory molecules 
and cytokine production profile (Berin, Shreffler 2008, Liu 2007). Differentiation of naive T 
cells into Th2-cells requires the stimulation of the IL4-receptor and T cell receptor 
(Romagnani 2004, Chatila et al. 2008). The provenance of IL-4 in this process is unclear. 
Innate immunity and its reaction to environmental cues, or the lack of them, may be a trigger; 
innate cells such as mast cells, basophils and NKT cells secrete IL-4 (Berin, Shreffler 2008, 
Romagnani 2004, Kronenberg 2005, Liu 2008). Activated naive T cells appear to secrete low 
levels of IL-4, which may act in an autocrine and paracrine manner to drive Th2 
differentiation, particularly if TH1-inducing signals are absent(Berin, Shreffler 2008). 
Intraepithelial and lamina propria lymphocytes have been shown to spontaneously secret IL-4 
and IFN-γ in non-inflammed gut (Carol et al. 1998). Furthermore, IL-4 potently inhibits TH1 
differentiation (Berin, Shreffler 2008, Romagnani 2004). The combination of inhibition with 
positive feedback may be the cue for Th2 differentiation (Berin, Shreffler 2008). The concerted 
stimulation of IL-4 and T cell receptors then leads to the expression of GATA-3, which is 
required and sufficient to determine the Th2 cell lineage (Zheng, Flavell 1997, Pai, Truitt & Ho 
2004). Th2-cytokines such as IL-4, IL-5 and IL-13 induce IgE production and eosonophilic 
activation (Kay 2001a). Circulating specific IgE antibodies to an antigen, e.g. CM, bind to mast 
cells and basofils (Kay 2001a). At subsequent CM exposure, the antigen binding leads to the 
crosslinking of these antibodies and further to the release of inflammatory reagents from 
effector cells (Herz 2008, Christensen et al. 2008). Lower numbers of activated basophils 
reportedly associate with development of clinical tolerance to CM (Wanich et al. 2009). 
Decrease in CM specific IgE levels may predict recovery from CMA (Garcia-Ara et al. 2004). 
Beyer et al reported that gut-residing lymphocytes from patients with CM-associated 
gastrointestinal immunological disorders produced more Th2 cytokines and less IL-10 and 
TGF-β in response to CM stimulation in vitro than lymphocytes from healthy individuals (Beyer 
et al. 2002). Lower levels of TGF-β production were also reported in lymphocytes of duodenal 
mucosa from children with food allergy, whereas no Th2-skewing was found compared to 
healthy control subjects (Perez-Machado et al. 2003). In non-IgE-mediated CMA, the 
immunological reaction is T-cell mediated, and remains poorly characterized (Sicherer, 
Sampson 2008). Figure 1 presents an overview of the antigen presentation and T cell 
differentiation leading to clinical manifestations of allergy. 
 
Oral desensitization appears to be a promising treatment for CMA (Staden et al. 2007, Meglio 
et al. 2008, Skripak et al. 2008). During treatment with increasing doses of oral CM 
administration, the majority of children with CMA become desensitized to CM. A large 
proportion of patients achieve longer term tolerance to CM (Staden et al. 2007, Meglio et al. 
2008, Skripak et al. 2008, Narisety et al. 2009). Further studies with larger number of patients 





Figure 1. Schematic overview of cellular mechanisms leading to allergy 
 
 




The gold-standard for CMA diagnosis is an oral, preferably placebo-controlled and double-
blind CM challenge after a successful elimination diet (Niggemann, Beyer 2007). In practice, 
the diagnosis is at times based on a history of CM-related symptoms combined with high levels 
of CM specific IgE (Sampson, Ho 1997, Sampson 2001). However, a diagnostic specificity of 
at least 90% may not be possible in regard to CM (Celik-Bilgili et al. 2005). CM-specific skin 
prick test is also used for diagnostics (Verstege et al. 2005), but it has the same caveats as 
specific IgE measurements (Breuer et al. 2004).   
 
Immunologically, CMA can be divided to an IgE-mediated and a non-IgE-mediated form 
(Sampson 1999, Sabra et al. 2003). The IgE-mediated form is usually defined as the patient 
having high detectable levels of CM specific IgE antibodies in serum or having a positive skin 
prick test (SPT) to CM. Threshold for CM specific IgE levels is commonly defined as 0.7 
kU/L or for higher specificity, 0.35 kU/L (Vanto et al. 1999). CM specific SPT is considered 
positive if the wheal diameter is 3 mm or more greater than the negative control (Verstege et 
al. 2005, Vanto et al. 1999).  The reaction to CM in IgE-mediated CMA is characteristically 
immediate: the symptoms arise within a few hours. They result from the release of 
proinflammatory mediators from mast cells and other effector cells upon crosslinking of 





tissue infiltration of neutrophils and basophils as well as Th2 cells and monocytes (Kay 2001a). 
Typical symptoms are urticaria, exanthema, angioedema, wheezing and vomiting.   
 
Non-IgE-mediated CMA is more difficult to diagnose than IgE-mediated CMA (Niggemann, 
Beyer 2007). The reaction probably is T cell mediated and delayed: Symptoms usually appear 
only several hours or days after allergen exposure (Kay 2001a). Typical symptoms are atopic 
dermatitis (Darsow et al. 2010), and diarrhea.  In combined forms, patients show both 





Cow’s milk allergy manifests itself in various symptoms affecting multiple organs, and most 
patients have more than one symptom (Host, Halken 1990, Sabra et al. 2003). Clinically, CMA 
can be categorized to immediate and delayed type. No clear consensus exists on the dividing 
time point: it may be set anytime between one hour and up to 24 hours.  This clinical 
categorization closely associates with the immunologic one: immediate symptoms are caused 
by IgE-mediated reactions. 
Immediate symptoms are often mucosal and cutaneous. They include urticaria, exanthema and 
angioedema, which usually appear within minutes after allergen exposure (Sampson 1999). 
Respiratory manifestations also develop rapidly and include allergic rhinitis, cough and 
wheezing. The most serious symptom in CMA is anaphylaxis (Kay 2001b), which is much rarer 
than other symptoms (Sampson 1999, Eigenmann 2002a). However, its incidence is more 
difficult to assess than for other symptoms since patients with a history of possible 
anaphylactic reaction are usually not challenged in a controlled manner. 
 
Delayed symptoms are mainly gastrointestinal such as vomiting, diarrhea and rarely even 
haematochezia (Sampson 1999, Rance et al. 1999); these symptoms may also arise in an 
immediate type reaction.  CMA is often associated with infantile atopic eczema, which appears 
in both immediate and with delayed form (Sampson 1999, Breuer et al. 2004, Rance et al. 
1999).   
Prognosis 
 
The prognosis for CMA is generally good.  CMA persists beyond the age of 3 years in a 
minority of patients (Host, Halken 1990, Saarinen et al. 2005).  High cow’s milk (CM) specific 
IgE levels (Vanto et al. 2004, Skripak et al. 2007, Dias, Santos & Pinheiro 2010) and strong 





mediated CMA has a better prognosis than IgE-mediated disease (Saarinen et al. 2005). 
Moreover, patients who tolerate baked milk appear to recover earlier than those who do not 
(Nowak-Wegrzyn et al. 2008). Several studies have reported that profiles of IgE binding to CM 
epitopes differ between patients who recover early and those whose CMA persists (Vila et al. 
2001, Cerecedo et al. 2008, Wang et al. 2010). This is discussed more in detail in the chapters 
“Epitope recognition by antibodies in cow’s milk allergy” in the literature review and in 
“Implications for CMA diagnostics and prognostics” in the discussion section. 
Table 1 summarizes results of several studies on the recovery rates in CMA.  
 
Table 1. Summary of recovery from CMA in four independent studies (Garcia-Ara et al. 2004, 
Saarinen et al. 2005, Vanto et al. 2004, Skripak et al. 2007) 







only or both 
Reference 
2 44 162 both Vanto et al. 2004 
3 69 162 both Vanto et al. 2004 
3 87 39 both Host, Halken 1990 
4 68 66 both Garcia-Ara et al. 2004
4 19 807 IgE Skripak et al. 2007 
4 77 162 both Vanto et al. 2004 
5 74 86 IgE Saarinen et al. 2005 
8-9 85 86 IgE Saarinen et al. 2005 
10 52 807 IgE Skripak et al. 2007 
 
 
The problem is that currently no accurate tools are available for prognostics on an individual 
level. Thus clinicians face difficulties in deciding on when to start incorporating CM into the 
diet of patients. Furthermore, specific immunotherapies such as oral desensitisation are being 
launched in the treatment of persistent CMA. Desensitisation protocols are rather 
cumbersome for the patient (Skripak, Wood 2009), and clinicians should have better diagnostic 






Genetics in cow’s milk allergy and other allergies 
 
Allergic disorders result from an interplay between genetic, epigenetic and environmental 
factors (Cookson 1999, von Mutius 2009, Le Souef 2009) . The genetic component is 
undoubtedly multifactorial (Cookson 1999, Bosse, Hudson 2007). Numerous genes, some 
increasing susceptibility and others with a protective effect, together affect the development of 
e.g. asthma (von Mutius 2009, Weiss, Raby & Rogers 2009). The risk alleles are most probably 
common variants that alter gene function but do not disrupt it (Cookson 1999). One approach 
for studying genetic factors in allergy is to investigate candidate genes that have functions 




Mutations in the filaggrin gene show associations with atopic eczema (Brown et al. 2008, 
O'Regan et al. 2009, van den Oord, Sheikh 2009). Dysfunction of the filaggrin protein disrupts 
the skin barrier, and may thus predispose to sensitization to harmless antigens (O'Regan et al. 
2009, Palmer et al. 2006).  Indeed, filaggrin gene mutations increase the risk for allergic 
sensitization (van den Oord, Sheikh 2009). The association of filaggrin mutations and food 
allergies have not been investigated to date (van den Oord, Sheikh 2009). Since eczema is a 
common symptom in CMA, the role of filaggrin mutations in CMA is interesting to 
investigate. Furthermore, a few studies have suggested that children could become sensitized 
to food allergens via skin (Hsieh et al. 2003). This could be explained by a defective skin 
barrier linked to filaggrin gene mutations (Weidinger et al. 2006). The hypothesis is of 
particular interest in the case of CMA since some infants develop CMA even during exclusive 
breastfeeding. 
Human leukocyte antigen II genes 
 
Human leukocyte antigen (HLA) II alleles are associated with the risk of several immunological 
disorders such as celiac disease and type I diabetes (Ilonen et al. 2002, Hermann et al. 2003, 
Tollefsen et al. 2006). Functionally HLA molecules are central to the development of an 
immune response. After endocytosis to antigen presenting cells (APCs), extracellular antigens 
are processed into peptides of 12-20 amino acids (Monaco 1995).  Antigen processing is 
regulated by synchronized functions of several proteases (Cresswell 2005). Class II molecules 
bind to a protein called the invariant chain that then directs the HLA molecules to 
compartments where antigenic peptides are transported (Monaco 1995, Roche 1996). The 
invariant chain furthermore blocks the binding of class II molecules to peptides prematurely in 
the endoplasmic reticulum and Golgi apparatus (Roche 1996, Pieters 1997). A proteolytic 
product of the invariant chain, called CLIP, then binds to the class II molecule, and only after 





1997). A protein called HLA-DM then facilitates the binding of the antigenic peptide to the 
binding groove of HLA molecules, which is composed of an α- and β-chain (Cresswell 2005, 
Roche 1996, Pieters 1997). These HLA-peptide complexes are transported on the cell surface 
of APCs where they present antigens to T cells for specific immune recognition (Cresswell 
2005, Klein, Sato 2000).  HLA genotype thus determines the repertoire of presented peptides 
to lymphocytes (Pieters 1997). 
 
Several studies have reported associations between HLA alleles and atopy and/or specific 
allergies. Cow’s milk allergy was associated with HLA-DQ7 (HLA-DQB1*0301) in an Italian 
patient sample (Camponeschi et al. 1997). However, a  larger Finnish study comparing 100 
CMA patients with healthy subjects, did not find any association between CMA and HLA A, 
B, Bw, C or DR antigens(Verkasalo et al. 1983). Studies on other food allergies have reported 
associations with HLA haplotypes. Peanut allergy was associated with DRB1*08, DRB1*12 
and DQB1*04 in Caucasian subjects (Howell et al. 1998) .  Boehncke and coworkers also 
reported an association between peanut allergy and HLA-DRB1*08 (Boehncke et al. 1998). 
They found associations between carrot allergy and HLA-DRB1*12, and grass pollen allergy 
and HLA-DQB*0301, whereas DRB1*01, DQA1*0101 and DQB1*0501 forming a haplotype 
were decreased among birch pollen allergy associated hazel nut allergy patients (Boehncke et al. 
1998) . Several studies have investigated the associations of HLA haplotypes with allergies to 
aeroallergens.  Birch pollen allergy, or possibly atopy more broadly, was reported to associate 
with HLA-DR7 (Senechal et al. 1999) . Stephan and coworkers detected no significant linkage 
between grass pollen, birch pollen, or cat dander specific IgEs and sharing of HLA-DPB, -
DRB, and -DQB, whereas these loci showed association with house dust mite specific IgE 
(Stephan et al. 1999) .  Another study reported that house dust mite sensitization was 
associated with HLA DRB1*07, while DRB1*04 conferred a protective effect (Kim et al. 2001) 
. Allergy to mugwort main allergen Art v1 was found to be restricted to HLA DRB*01 (Jahn-
Schmid et al. 2005) . The HLA alleles DRB1*0701 and DQB1*02 were associated with 
cockroach allergy, and with atopy in general (Kalpaklioglu, Turan 2002) . HLA DQB1*05, 
especially 0501, but also 0502 and 0503, conferred susceptibility to develop IgE antibodies 
against organic acid anhydrates (Jones et al. 2004) . Table 2 summarizes these reported 
associations. 
 
The association of HLA genotypes with humoral responses to allergens has been investigated 
in few studies, and only rarely the intensity of the response has been studied. Specific IgG 
response to Ra5 (Amb5), a ragweed allergen, was associated with HLA-Dw2 in a Caucasian 
population (n=447) (Marsh et al. 1982). Immune response to the grass pollen allergen Lol p III 
HLA-DR3 was reported to associate with a specific sequence shared by DR3, DR11 and DR6 
(Ansari et al. 1991). In a heterogeneous population of allergic patients, HLA-DRB1*1101 
and/or 1104 were associated with  the presence of specific IgG and IgE antibodies to Par o 1, 





Table 2. Reported positive associations of HLA II haplotypes with different allergies 
 
 
Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 
 
The PTPN22 gene encodes a lymphoid tyrosine phosphatase (LYP) that negatively regulates 
T-cell responses. This function has raised interest in whether mutations in the gene are 
associated with immunological disorders, but few studies to date have addressed allergy. A 
mutation (1858 SNP or R620W allele) in the PTPN22 gene is associated with several 
autoimmune diseases (Bottini et al. 2004, Michou et al. 2007, Smyth et al. 2008). No 
association has yet been found with asthma (Majorczyk et al. 2007)  or high total serum IgE 
(Maier et al. 2006).   
Allergy Positive HLA association Reference 
Cow’s milk  DQ7 (QB1*0301) Camponeschi et al 1997 
Cow’s milk  no association Verkasalo  et al 1983 
Peanut  DRB1*08, DRB1*12, 
DQB1*04 
Howell  et al 1998 
Peanut  DRB1*08 Boehncke  et al 1998 
Carrot  DRB1*12 Boehncke  et al 1998 
Grass pollen  DQB*0301 Boehncke  et al 1998 
Birch pollen DR7 Senechal  et al 1999 
House dust mite DRB1*07 Kim  et al 2001 
Mugwort (Art v1) DRB*01 Jahn-Schmid  et al 2005 
Cockroach DRB1*0701, DQB1*02 Kalpaklioglu  et al 2002 





The role of antibodies in cow’s milk allergy and tolerance 
 
Physiological humoral response to cow’s milk 
 
Fetal lymphocytes appear to be primed by CM antigens already prenatally (Szepfalusi et al. 
1997). At birth, infants have IgG class antibodies to CM acquired from the mother by 
transplacental transportation (Kemeny et al. 1991, Holt, Jones 2000). Neonates produce 
immunoglobulins at low levels (Holt, Jones 2000). Later during infancy immune responses 
such as antibodies to food allergens increase (Cummins, Thompson 1997) and decline by the 
age of one year (Husby 2000).  The physiological response infants develop after CM exposure 
is dominated by IgG class antibodies (Tainio et al. 1988, Vaarala et al. 1995), IgG1 subclass in 
particular (Kemeny et al. 1991). The specific IgG levels rise during the first year of life (Tainio 
et al. 1988, Kemeny et al. 1991).  Specific IgA and IgM to CM are absent at birth, but infants 
produce them even during exclusive breast feeding i.e. during minimal CM exposure (Tainio et 
al. 1988, Kuitunen, Savilahti 1995). Physiological response entails also the production of 
specific IgE antibodies, although in lower quantity than other immunoglobulins (Hattevig, 
Kjellman & Bjorksten 1993).  
Immunoglobulin class E 
 
Serum levels of immunoglobulin E are much lower than those of IgG class antibodies, even in 
sensitized individuals (Corry, Kheradmand 1999). IgE production in B cells is induced by Th2 
cytokines IL-4, IL-5, IL-6, IL-9 and IL-13, and inhibited by Th1 cytokines IFN-γ and IL-2 
(Corry, Kheradmand 1999). Antigen stimulation of B cell receptor combined with co-
stimulatory molecules also promotes immunoglobulin class-switching to IgE (Corry, 
Kheradmand 1999). When IgE mediates antigen uptake, dendritic cells show augmented 
antigen presentation and induction of Th2 responses to memory T cells compared with antigen 
uptake mediated by IgG subclass antibodies (Lundberg et al. 2008). 
 
Already neonates reportedly have antigen-specific IgE antibodies as measured in cord blood 
(Holt, Jones 2000). In addition to circulating in the blood, IgE antibodies may be secreted to 
the gut lumen; the function of secretory IgE remains, however, unclear (Corry, Kheradmand 
1999, Negrao-Correa, Adams & Bell 1996).  Sensitization to food allergens is manifested by 
heightened production of specific IgE antibody (Jenmalm, Bjorksten 1999, Bottcher et al. 
2002). Higher levels of IgE antibodies to CM proteins are associated with persisting CMA 
compared to patients who recover from CMA early (Garcia-Ara et al. 2004, Vanto et al. 2004, 
Skripak et al. 2007, Sicherer, Sampson 1999).  A slower rate of decrease in specific IgE levels 
over time may predict persistence of CMA as well as hen’s egg allergy (Shek et al. 2004). 





IgE (Meglio et al. 2008, Niederberger et al. 2004, Nouri-Aria et al. 2004, Jones et al. 2009) 
while others have not observed any significant change (Skripak et al. 2008, Francis et al. 2008).   
Immunoglobulin isotype class G  
 
Whether IgG class antibodies present purely physiological responses to food allergens or 
actually play a role in the development of tolerance or allergy, is controversial (Barnes 1995, 
Keller et al. 1996). Recent research presents several lines of evidence to support the hypothesis 
that IgG antibodies, IgG4 in particular, do contribute to allergy and tolerance development, 
but the conclusions remain controversial.  
 
Th2-deviation may be associated with reduced capacity to mount IgG responses (Le Souef 
2009). While the Th2-cytokine IL-4 induces class switching in B cells to both IgE and IgG4 
(Punnonen et al. 1993),  IL-10 up-regulates the secretion of IgG4 and inhibits IgE production 
(Jeannin et al. 1998, Satoguina et al. 2005, Meiler et al. 2008a). Specific IgG4 functions by 
blocking the binding of specific IgE to allergen(Nouri-Aria et al. 2004, van Neerven et al. 1999, 
Wachholz et al. 2003, Ejrnaes et al. 2006). A mechanism crucial to the anti-inflammatory 
function of IgG4 seems to be the Fab arm exchange (van der Neut Kolfschoten et al. 2007). 
 
A specific IgG4  response to the food antigens may be physiological, the result of continuous 
exposure to the antigen (Tay et al. 2007, Stapel et al. 2008). On the other hand, higher specific 
IgG levels to the CM protein β-lactoglobulin (Oldaeus et al. 1999) and hen’s egg ovalbumin 
(Jenmalm, Bjorksten 1999, Eysink et al. 1999) have been associated with increased incidence of 
atopic diseases, plausibly reflecting  a Th2-deviation (Jenmalm, Bjorksten 1999).  Lilja et al 
reported that CM specific IgG and IgE levels correlated positively in infants, and suggested 
that some individuals are “high responders” and some “low responders” in their humoral 
response to  oral antigens overall (Lilja et al. 1991). In children sensitized to hen’s egg, specific 
IgG1 levels increased during the first year of life more in children whose allergy persisted 
compared to those who recovered early, whereas specific IgG4 levels did not differ between 
the groups (Vance et al. 2004). Studies on cat exposure and atopic disorders in adolescents 
have reported higher specific IgG4 levels and immunological tolerance to cats in individuals 
with continuous cat exposure at home (Platts-Mills et al. 2001, Hesselmar et al. 2003). The 
finding may suggest a role of IgG4 in tolerance, although IgG4 levels showed no association 
with atopic disorders (Platts-Mills et al. 2001, Hesselmar et al. 2003). Higher specific IgG4 
levels were also associated with high dose exposure to birch aeroallergen at the postnatal 
period (Kihlstrom et al. 2005). 
 
Upregulation of allergen specific IgG4 production induced by IL-10 is, however, also related to 





increased levels of IgG4 antibodies often indicate that anti-inflammatory processes are 
activated (Aalberse et al. 2009). Several studies on aeroallergen specific immunotherapy have 
reported increased specific IgG4 levels in patients whose allergy improved clinically (Nouri-
Aria et al. 2004, Francis et al. 2008, Mothes et al. 2003, Bussmann et al. 2007), furthermore 
simultaneously with increasing numbers of circulation Tregs (Pereira-Santos et al. 2008). 
Results from immunotherapeutic settings in food allergies have reported similar phenomena. A 
shortcoming of these studies is that they have largely failed to demonstrate long-term recovery, 
but rather desensitization during and shortly after the active therapy. An exception is the study 
by Meglio and coworkers, in which  children were followed for over four years after oral 
desensitization. Long-term tolerance was associated with decreased specific IgE levels (Meglio 
et al. 2008). Contrarily, CM-specific IgE levels remained at baseline levels in another study with 
shorter follow-up and where only desensitization during immunotherapy to CM could be 
reported (Skripak et al. 2008). This study also investigated specific IgG, most notably IgG4, 
and observed an increase in their levels (Skripak et al. 2008). In a study on patients with CMA 
but asymptomatic to heated CM, similarly an increase in casein specific IgG4 levels was seen 
after a three-month period of consuming heated CM, whereas specific IgE levels did not 
change (Nowak-Wegrzyn et al. 2008). Children with peanut allergy who became desensitized 
during peanut allergy immunotherapy, showed increased specific IgG4 levels and decreased 
specific IgE levels (Jones et al. 2009).   
 
A few studies have investigated the natural development or maintenance of tolerance to food 
allergens without therapeutic intervention. Clinical improvement of symptoms in a population 
of patients with hen’s egg allergy was associated with an increase in ovalbumin specific IgG4 
and decrease in specific IgE (Lemon-Mule et al. 2008). In children with milk and/or egg 
allergy, low levels of IgG4 to ovalbumin and/or β-lactoglobulin indicated the need for 
prolonged elimination diet (Tomicic et al. 2008). A study comparing non-atopic individuals 
with subjects with CMA reported that the maintenance of tolerance to CM proteins associated 
with higher levels of CM specific IgG4 levels (Ruiter et al. 2007a).  
Immunoglobulin class A  
 
The production of IgA is more abundant than that of any other antibody class (Macpherson et 
al. 2001). The large majority is secreted to mucosal surfaces, most importantly in the gut 
(Macpherson et al. 2001).  
 
Serum IgA is produced in small quantities compared with the secretory antibody or with serum 
IgM and IgG (Macpherson et al. 2001). It may, however, play a role in the development of 
tolerance. The mechanism differs from IgG4: specific IgA does not inhibit IgE binding (van 
Neerven et al. 1999, Pilette et al. 2007). The production of IgA seems to be independent of T 
helper cells (Meiler et al. 2008a), to be associated  with local TGF-β expression, and to induce 






The relatively high prevalence of allergies among patients with IgA deficiency 
(Aghamohammadi et al. 2009) advocates a role for IgA antibodies in the protection against 
allergies and/or the development of tolerance. Low total (Savilahti et al. 1991) and CM specific 
(Jarvinen et al. 2000) IgA in colostrums has been associated with the risk of CMA. High 
intestinal IgA in infants reportedly associated with reduced the risk for IgE-mediated allergies 
(Kukkonen et al. 2009). However, another study observed no association of breast milk IgA or 
cytokine levels with salivary IgA nor development of atopy in children up to the age of two 
years (Bottcher, Jenmalm & Bjorksten 2003). Studies on grass pollen immunotherapy have 
reported that specific IgA (Francis et al. 2008) or IgA2 (Pilette et al. 2007) levels in peripheral 
blood rose as the allergic symptoms improved, and in a study on birch allergen vaccine specific 
IgA levels reportedly increased during the immunotherapy(Niederberger et al. 2004). Bottcher 
et al reported that infants who developed allergy had higher levels of total and allergen-specific 
IgA antibodies in serum (Bottcher et al. 2002).  However, they observed that sensitized infants 
with no allergic symptoms had higher levels of specific IgA than symptomatic, sensitized 
infants (Bottcher et al. 2002). Their results thus suggest a role for specific IgA in the 
maintenance of clinical tolerance. Yet, Shek et al observed that in patients with IgE-mediated 
CMA, cow’s milk protein specific IgE levels correlated positively with levels of specific 
immunoglobulins of other isotypes (IgA, IgG1, IgG4) (Shek et al. 2005).  
Epitope recognition by antibodies in cow’s milk allergy 
 
 Patients with cow’s milk allergy typically react to several cow’s milk proteins, while the four 
proteins in the casein fraction (αs1-, αs2-, β- and κ-casein) as well as α- lactalbumin and β-
lactoglobulin are considered major allergens (Savilahti, Kuitunen 1992, Wal 2004). Both 
conformational and sequential epitopes elicit antibody responses (Wal 2004, Sathe, Teuber & 
Roux 2005, Lin, Sampson 2009). β-lactoglobulin has a globular structure and thus 
conformational epitopes, whereas the structure of caseins is more linear (Sanchez, Frémont 
2002). Nevertheless, β-lactoglobulin also retains much of its immunoreactivity after chemical 
processing (Selo et al. 1999). Sequential epitopes are thought to be more important in food 
allergies since proteins are mostly digested in the gut into peptides and aminoacids and thus 
lose their conformational structures; also heating and other processing reduces conformational 
epitopes (Sathe, Teuber & Roux 2005, Lin, Sampson 2009). Antigenic peptides are usually at 
least eight aminoacids long (Herz 2008, Bannon, Ogawa 2006). 
 
Epitope profiling of IgE antibodies has given additional insight into the relation between 
antibody responses and clinical reactivity in CMA. The pattern of IgE epitope recognition 
varies remarkably between individual patients with CMA (Wang et al. 2010, Cocco et al. 2007, 
Han et al. 2008). Patients with persisting CMA tend to recognize a wider variety of sequential 
IgE epitopes than patients with transient CMA (Vila et al. 2001, Cerecedo et al. 2008, Wang et 





diversity of IgE epitope recognition has been linked to the severity of symptoms. Furthermore, 
some IgE recognition of certain sequential epitopes especially in caseins is associated with 
persisting CMA (Vila et al. 2001, Cerecedo et al. 2008, Jarvinen et al. 2002). Similar findings 
have been reported in hen’s egg allergy (Jarvinen et al. 2007).  Wang et al compared children 
clinically reactive to all CM-derived foods with those who tolerated heated CM as well as those 
who had outgrown CMA (Wang et al. 2010). They found that children who tolerated heated 
CM had similar CM epitope binding patterns to those who had outgrown CMA (Wang et al. 
2010). These two groups had lower affinity CM epitope binding by IgE than children who 
were reactive to all CM forms (Wang et al. 2010). 
 
We do not know much, however, about how epitope recognition in allergy evolves over time 
and how it changes during tolerance development.  A study in children with peanut allergy 
reported that peanut epitope binding by IgE remained stable over a twenty-month time period 
(Flinterman et al. 2008).  
 
Little is known about the epitope recognition by IgG4 and IgA antibodies in food allergies. An 
early study based on enzymatic protein lysis into peptides reported that children with CMA 
had higher IgG levels to native in particular, but also to pepsin hydrolyzed β-lactoglobulin, 
than healthy control subjects (Duchateau et al. 1998). According to a recent study, CM epitope 
binding by IgG4 as measured with a microarray based method was not associated with clinical 
features of CMA (Wang et al. 2010). 
 
The investigation of epitope recognition by IgE in food allergies began with the generation of 
epitope with enzymatic cleavage (Selo et al. 1999, Duchateau et al. 1998). This method could 
screen only a limited variety of epitopes (Lin, Sampson 2009). The next generation technology 
was based on SPOT membrane (Jarvinen et al. 2002). This method detects IgE binding even at 
rather low specific IgE levels (Beyer et al. 2003), but has a relatively high signal/noise-ratio and 
also a limited number of target peptides per assay (Lin, Sampson 2009). It was also labour-
intensive, required high allergen specific IgE-levels and consumed large volumes of serum 
(Lin, Sampson 2009, Shreffler et al. 2005). The next generation peptide microarray based 
immunoassay has greatly improved possibilities to investigate the subject. It enables a large 
number of samples to be processed simultaneously, consumes only small amount of serum and 
is considerably more sensitive than SPOT membrane technology, thus allowing the study of 
also sera with low specific IgE levels (Shreffler et al. 2005, Beyer et al. 2005, Lin et al. 2009). 
Furthermore, the microarray-based immunoassay produces quantitative data in contrast to the 
qualitative or at most semiquantitative data of SPOT membrane technology. Comparison of 






Regulatory T cells in allergy 
 
Regulatory T-helper cells (Tregs) suppress the functions of other lymphocytes (Annunziato et 
al. 2002). They represent approximately 5-10% of peripheral CD4+ cells. The dysfunction of 
Tregs appears to contribute to the immunopathology of allergies (Tang, Bluestone 2008, Akdis, 
Akdis 2009). 
Subpopulations of regulatory T cells  
 
Regulatory T cells are considered to be the primary mediators of peripheral tolerance (Vignali, 
Collison & Workman 2008). T cells with suppressive function have been observed in 
experimental settings since the 1970s, but  during the last decade their existence has attained 
substantial and ever-growing evidence both in vitro and in vivo, and both in animal models and 
humans (Tang, Bluestone 2008, Chen et al. 1994, Groux et al. 1997). Characterization of Tregs 
is, nevertheless, still not entirely established. Several subpopulations have been distinguished. 
“Natural” Tregs originate in the thymus during ontogeny, and according to current knowledge, 
always express the transcription factor forkhead box protein 3 (FoxP3) (Tang, Bluestone 
2008). Other Treg subpopulations are induced from naive T-cells in the periphery and called 
adaptive Tregs (Kretschmer et al. 2005, Bluestone, Abbas 2003, Walker et al. 2005, Apostolou 
et al. 2008).  These can be either FoxP3 positive or negative (Sun et al. 2006, Chen et al. 2003, 
Feuerer et al. 2009). Distinct adaptive Treg subpopulations include “Tr1” cells that produce 
high levels of IL-10 and varying levels of  TGF-β,IL-5, low amounts of IFN-γ and IL-2, but no 
IL-4 (Groux et al. 1997, Levings et al. 2001, Wu et al. 2007).  Tr1 cells do not constitutively 
express Foxp3 (Vieira et al. 2004). They appear to be of special importance in controlling 
immune responses to environmental antigens at body surfaces such as lungs and the gut 
(Rubtsov et al. 2008). T helper type 3 cells are characterized by suppressive function and the 
production of transforming growth factor β (TGF- β)(Levings et al. 2001, Carrier et al. 2007, 
Wan, Flavell 2008). In addition, inducible T cells with suppressive function have been 
characterized: CD8+ T suppressor cells, natural killer T cells (Kronenberg 2005), CD4-CD8-T 
cells (Zhang et al. 2000)and γδ T cells (Hayday, Tigelaar 2003). 
Studies have reported have numerous modes of function for Tregs of different subtypes 
ranging from cell-cell-contact to the secretion of cytokines, but their relative importance in vivo 
remains to be elucidated (Vignali, Collison & Workman 2008). 
 
Markers for regulatory T cells 
 
None of the current markers for identifying Tregs is definitive: effector cells also express these 





The majority of Tregs express the surface marker CD25, a high-affinity receptor for IL-2 (IL-
2Rα) (Itoh et al. 1999), and the transcription factor FoxP3 forkhead box protein 3 (FoxP3) 
(Hori, Nomura & Sakaguchi 2003, Huehn, Polansky & Hamann 2009). Although all T cells 
express CD25 upon activation (Fontenot et al. 2005), high expression of CD25 seems to 
stabilize expression and maintenance of a Treg phenotype (Komatsu et al. 2009). Low 
expression of the surface marker CD127, an IL-7 receptor, distinguishes T cells with 
suppressive function, and the majority of them are FoxP3 positive (Liu et al. 2006, Seddiki et 
al. 2006, Bayer et al. 2008).  
 
Mutations in the FoxP3 gene are the cause of IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome), which is manifested as multiorgan 
autoimmune diseases, allergy and inflammatory bowel disease (Bennett et al. 2001). This 
finding lead to the identification of FoxP3 as the central regulatory gene of natural Treg 
commitment (Hori, Nomura & Sakaguchi 2003, Tai et al. 2005). Indeed, forced expression of 
the FoxP3 gene in CD4+CD25- non-Tregs resulted in a suppressive phenotype and the 
expression of markers associated with Tregs (Hori, Nomura & Sakaguchi 2003, Fontenot, 
Gavin & Rudensky 2003). Foxp3 is a transcriptional repressor and activator that interfers with 
T cell receptor (TCR)-dependent activation of genes. FoxP3 expression is induced by the 
interplay of relatively short and weak T cell receptor activation, co-stimulatory molecules and 
cytokines that remain to be fully identified (Huehn, Polansky & Hamann 2009) . Its function is 
required for Treg cell suppressor activity, but largely it rather amplifies and fixes pre-
established molecular features of Tregs, such as anergy and dependence on paracrine IL-
2(Gavin et al. 2007). In addition, Foxp3 stabilizes Treg cell lineage through modification of cell 
surface and signaling molecules so that the cells adapt to the signals required to induce and 
maintain Tregs (Gavin et al. 2007).  
 
 
FoxP3 is not, however, the kind of master gene of Treg development in humans as was 
purported some years ago (Vignali, Collison & Workman 2008, Feuerer et al. 2009). It seems 
that a higher level of regulation upstream of Foxp3 determines the lineage (Hill et al. 2007). On 
the other hand, activation induces FoxP3 expression in all T cells, and in T effector cells this 
transient FoxP3 expression does not necessarily elicit suppressive function (Feuerer et al. 2009, 
Allan et al. 2007). Indeed, continuous FoxP3 expression is required for the maintenance of 
Treg phenotype (Williams, Rudensky 2007). FoxP3+ cells seem to be divided into at least two 
populations: CD4+CD25high cells that have stable FoxP3 expression and are committed to 
the Treg lineage, and CD4+CD25- cells that are not fully committed, have an unstable FoxP3 
expression and may start responding to cytokines directing them to Th effector cells (Komatsu 
et al. 2009). Transforming growth factor β (TGF-β) seems to be crucial in maintaining the 
expression of FoxP3 and the Treg phenotype in CD4+CD25- (Komatsu et al. 2009) . In 
FoxP3+ T cells, epigenetic control of FoxP3 expression appears to determine the stability of 






FoxP3 interacts with the transcription factor called nuclear factor of activated T cell (NFAT) 
to repress expression of the cytokine IL2, and upregulate expression of the Treg markers 
CD25 and cytotoxic T lymphocyte–associated antigen 4 (CTLA4) (Wu et al. 2006). NFAT 
either stimulates cytokine expression leading to T cell activation by interacting with the 
transcription factor AP-1, or suppresses cytokine expression which leads to T cell tolerance by 
interacting with Foxp3 (Wu et al. 2006, Bettelli, Dastrange & Oukka 2005, Bopp et al. 2005).  
In knockout mice, double deficiency for NFATc2 and NFATc3 causes massive 
lymphadenopathy, splenomegaly and a strong increase in serum IgE and IgG1 levels (Bopp et 
al. 2005). It also renders CD4+ CD25- T cells unresponsive to suppression, although it does 
not interfere with the development or function of CD4+CD25+ Tregs (Bopp et al. 2005).  
 
CTLA-4  is constitutively expressed in CD25+CD4+ regulatory T cells in mice (Takahashi et 
al. 2000) and human in thymocytes (Annunziato et al. 2002). Its blockade in mice results in the 
spontaneous development of autoimmune disorders(Takahashi et al. 2000). A recent study on 
mice with CTLA-4 deletion in CD4+FoxP3+ cells reported spontaneous development of 
systemic lymphoproliferation, fatal T cell–mediated autoimmune disease, and hyperproduction 
of immunoglobulin E, as well as potent tumor immunity(Wing et al. 2008). Treg-specific 
CTLA-4 deficiency adversely affected especially the Treg-mediated down-regulation of CD80 
and CD86 expression on dendritic cells, and thus CTLA-4 may be of particular importance in 
the control of T effector cell activation induced by antigen presenting cell (Wing et al. 2008). 
Transfection of resting human T cells with CTLA-4 conferred suppression, which is facilitated 
by but not dependent of FoxP3 expression (Zheng et al. 2008). In addition to enabling the 
suppressive function of natural Tregs (Wing et al. 2008),  CTLA4 may also induce suppressive 
Tregs in the absence of FoxP3 expression (Zheng et al. 2008). Read et al reported that 
CD4+CD25+ Tregs which suppressed inflammation in the gut, constitutively expressed 
CTLA-4 (Read, Malmstrom & Powrie 2000). 
 
The number of Tregs as well as the expression of NFAT and cytokines in T cells, are also 
enhanced by the calcium sensors STIM1 and STIM2 (Oh-Hora et al. 2008). Activated 
CD4+CD25+  cells preferentially express the T cell immunoglobulin domain, mucin domain 
(Tim-3), which plausibly reduces Th1-driven immune responses (Sanchez-Fueyo et al. 2003). 
The migration and possibly de novo generation of Tregs suppressing Th2 type cells is induced by 
IL-16 at inflammation sites (McFadden et al. 2007). In allergic inflammation, Treg function 
involves IL-10, which further enhances TGF-β secretion by Tregs (Jutel et al. 2003, Joetham et 
al. 2007). The deviation from IFN-γ secreting Th1 cells, characterized by the transcription 
factor Tbet (Szabo et al. 2000), and/or of IL-5 and IL-13 secreting Th2 cells, defined by 
GATA3(Zheng, Flavell 1997, Pai, Truitt & Ho 2004),  to IL-10 and TGF-β secreting Tregs is 
essential for the induction of both tolerance in allergic patients and normal mucosal immunity 
in nonatopic individuals (Jutel et al. 2003).   
 
Other genes reported to have a characteristic expression profile in Tregs include CD103, G 






Figure 2 summarizes the interaction of central Treg markers. 
Recent research further complicates the picture of transcription factors expressed in Tregs. T-
bet, which is the master regulator of Th1 cells, and IRF4, which plays a role in Th2 and Th17 
differentiation, appear to participate in the suppressive function of Tregs (Feuerer et al. 2009).  
 
 




The role of regulatory T cells in allergies 
 
Allergies result from an aberrant immunological response to environmental antigens, including 
a dysfunction of T regulatory cells (Tregs) (Ling et al. 2004, Lin et al. 2005).  Natural, inducible 
as well as unconventional Tregs, especially of the Tr1 type, play an important role in both 
tolerance induction and allergy (Akdis, Akdis 2009, Cottrez et al. 2000, Akdis 2006, Saurer, 
Mueller 2009). The balance between Th2 and Treg functions is essential to the development of 
tolerance (Akdis et al. 2004, Francis, Till & Durham 2003).  FoxP3 directly interacts with 
GATA-3 and thus suppresses the expression of cytokines upregulated byt GATA-3 such as IL-
4, IL-5 and IL-13 (Dardalhon et al. 2008). The skewing of effector T cells into Tr1 cells has 
emerged as a crucial phenomenon in the development of tolerance to harmless environmental 
antigens (Akdis, Akdis 2009, Taylor et al. 2006). Some evidence suggests that CD4+CD25+ 
Tregs may not be as efficient in inhibiting Th2 function as they are in inhibiting Th1 function 
(Cosmi et al. 2004). 
 
Several studies have reported higher numbers of putative Tregs in patients with atopy or 
allergic symptoms compared with non-atopic subjects (Akdis, Akdis 2009), but also opposite 





the most widely used marker combination, CD4+CD25high variably combined with FoxP3-
positivity, is not necessarily very accurate in identifying Tregs (please see above the chapter on 
Treg markers) (Romagnani 2006). Suppressive in vitro experiments nevertheless add to the 
reliability of the results.  
 
Patients with atopic dermatitis and/or bronchial asthma had lower FoxP3 expression in CD4+ 
cells than healthy control subjects, and CD4+FoxP3+  percentage of PBMCs correlated 
negatively with total  IgE levels (Orihara et al. 2007). Lee et al reported that circulating Tregs 
were fewer in children with bronchial asthma or allergic rhinitis than in healthy control 
subjects, but on the other hand patients with more severe allergic symptoms had higher Treg 
numbers than those with milder symptoms (Lee et al. 2007). Increase in circulating Tregs has 
been reported to associate with the induction of tolerance in specific immunotherapy (Pereira-
Santos et al. 2008). PBMCs extracted from patients during aeroallergen immunotherapy 
showed increased numbers of CD4+CD25+ cells that had allergen specific suppressive 
function that was dependent on IL-10 and TGF-β signals (Jutel et al. 2003). Patients with 
active hayfever reportedly had weaker Treg suppressive function to effector T cell proliferation 
and IL-5 production upon antigen stimulation than atopic patients without symptoms, and 
non-atopic subjects had the strongest Treg suppressive function (Ling et al. 2004).  Contrarily, 
Jartti et al reported that in pediatric patients with family history of atopy the proportion of 
CD4+CD25high cells to CD4+ cells correlated positively with pollen-sensitization and IL-5, 
IL-10 and IL-13 production; however, no functional difference of Tregs was seen between 
study groups(Jartti et al. 2007). Maggi et al demonstrated that antigen specifc Tregs, both from 
patients allergic to the antigen and from non-atopic subjects, suppressed cytokine production 
by effector Tcells upon co-culture with specific antigen loaded dendritic cells (Maggi et al. 
2007). A result significantly opposed to many of the afore mentioned studies was reported by 
Reefer et al (Reefer et al. 2008). They found that in patients with atopic dermatitis and high 
total IgE levels, CD25 high cells expressing Foxp3, CCR4 and CTLA-4 were more numerous 
than in subjects with low total IgE levels (Reefer et al. 2008). Furthermore, these cells rather 
induced than inhibited Th2 function (Reefer et al. 2008). 
 
A few studies have addressed the question of tissue homing and localization of Tregs in atopic 
disorders. House dust mite immunotherapy was observed to induce IL-10 expressing PBMCs, 
also positive for CD4+CD25+, that expressed elevated levels of surface molecules related to 
peripheral tissue homing (Gardner et al. 2004). Grass pollen immunotherapy was associated 
with increased numbers of CD4+ FoxP3+ and CD25+FoxP3+ cells during pollen season 
compared with the numbers before immunotherapy (Radulovic et al. 2008). Out of the season 
numbers of these cells were higher in patients in immunotherapy than in untreated patients 
with hay fever (Radulovic et al. 2008). Sublingual grass pollen immunotherapy showed 
association with increased number of FoxP3 expressing cells in oral epithelium (Scadding et al. 
2010). In atopic dermatitis, functional Tr1 cells as well as TGF-β and IL-10 were found in the 






The role of Tregs in food allergies appers to conform to the observations in other allergies. A 
genetic defect in Treg function, i.e. a variant of human IPEX caused by a FoxP3 mutation, 
leads to severe food allergies (Torgerson et al. 2007). A recent study suggests that weaker 
responses of effector T cells to suppressive Tregs may predispose infants to egg allergy (Smith 
et al. 2008). Research on CMA has reported that patients with CMA who had become tolerant 
to CM had higher number of circulating CD4CD25 T cells (Karlsson, Rugtveit & Brandtzaeg 
2004) or allergen specific FoxP3+CD25hiCD27+, CTLA4+, CD45RO+CD127-  (Shreffler et al. 
2009) than patients with clinical reactivity to CM. In duodenal biopsies, FoxP3+ cells were 
more frequent in patients with food allergy compared with healthy subjects or with patients 
with Crohn’s disease (Westerholm-Ormio et al. 2010). Furthermore, untreated food allergy was 
associated with higher numbers of FoxP3+ cells compared with patients on an elimination diet 
(Westerholm-Ormio et al. 2010). The lower ratio of FoxP3 mRNA expression to the number 
of FoxP3+ cells in patients with untreated food allergy suggested a lower activity of these cells 
in comparison with healthy subjects (Westerholm-Ormio et al. 2010). 
 
 
A paradigm for the development of oral tolerance and cow’s milk allergy   
 
The quality and intensity of immune responses an infant mounts to CM antigens partly depend 
on genetic factors. An essential environmental factor is the timing of first CM exposure: early 
exposure induces pronounced humoral responses. Gut permeability affects the antigen load 
that GALT gets in contact with. Increased gut permeability may, furthermore, allow potentially 
more immunogenic undigested proteins to pass the gut barrier. In physiological conditions, 
high antigen exposure predominantly results in T cell anergy, whereas low exposure leads to 
the activation of Tregs. Dendritic cells residing in GALT play a central role in presenting 
antigens and inducing Treg function. Several different kinds of Tregs are present in the gut, 
and Tregs that have acquired antigen specificity also circulate in the blood. Tregs suppress 
cytokine production by effector T cells, such as IL-4 production by Th2 cells. IL-10 producing 
Tr1 induce IgG4 production while inhibiting IgE production. IgA production is induced by 
TGF-β-secreting Tr3 cells. Both IgG4 and IgA antibodies promote tolerance rather than 
sensitization, and indeed physiological humoral responses to CM in infants are dominated by 
CM specific IgG and IgA antibodies.  
 
Th2 dominated response to CM exposure and failure to induce oral tolerance result in CMA, 
which usually develops during the first year of life.  The majority of patients recover, however, 
by toddler age. The immunological mechanisms behind the natural development of tolerance 
in CMA are not fully understood. The trigger for tolerance development is elusive. It might be 
that during elimination diet CM specific effector T cells are devoid of antigen stimulation and 
their populations gradually diminish. In contrary, the trigger might as well be unintentional, 





recovery from allergy, Tregs, Tr1 cells in particular, become activated. They most importantly 
suppress Th2 cell proliferation and cytokine production. In addition, activated Tr1 cells secrete 
IL-10, which shifts IgE production in B-cells towards IgG4 production. Specific IgG4 
antibodies block the action of IgE of same specificity, and thus reduce IgE-mediated allergic 
reactions. Antigen specific IgA, induced by TGF-β, is also related to tolerance development, 
plausibly in part by inducing IL-10 production. Non-IgE mediated CMA subsides more rapidly 
than IgE-mediated allergy, which might be due to the fact that Tregs can directly suppress 
effector Tcells and do not need to additionally dampen antibody production and binding.  
 
Recent research has improved our understanding on how physiological induction of tolerance 
is disrupted in CMA and how it is regained in clinical recovery from CMA. Still, many 





Aims of the study 
 
 
1. To evaluate the impact of genetic factors, especially HLA II, filaggrin and PTPN22, on the 
risk of cow’s milk allergy and on the immune responses to dietary antigens. 
 
 
2. To investigate the role of humoral responses to cow’s milk in the development of oral 
tolerance and allergy. To furthermore characterize the profiles and dynamics of circulating 
specific antibodies binding to cow’s milk epitopes.  
 
 
3. To investigate how expression of genes with immunological functions and specific 
humoral responses differ between patients with CMA and non-atopic children, and 
furthermore between patients with persisting CMA and patients with early recovery.  
 
 











The same population was investigated in all four original publications. For study IV, nine new 
patients with active CMA were recruited (see below).  Informed and written consent was 
received from infants’/children’s parents, and at later age also from children themselves. The 
Ethics Committee of the Hospital for Children and Adolescents, University of Helsinki, 
approved of the studies.  
 
The population has been studied, predominantly from the clinical perspective, previously 
(Saarinen et al. 1999, Saarinen et al. 2005, Saarinen et al. 1999, Saarinen, Savilahti 2000, 
Saarinen, Savilahti 2000, Saarinen, Suomalainen & Savilahti 2001, Saarinen, Sarnesto & 
Savilahti 2002, Saarinen, Sarnesto & Savilahti 2002, Savilahti, Saarinen 2009). The population 
was part of a population-based cohort of 6209 full-term newborn infants who were recruited 
between August 1994 and November 1995 in three maternity hospitals in the Helsinki 
metropolitan region. They participated in a prospective, double-blind, randomized trial on early 
feeding and the emergence of CMA (Saarinen et al. 1999). At all maternity hospitals (mean 
hospital stay 4 days), exclusive breast feeding was encouraged.  The 5385 (87%) infants who 
required supplementary feeding were randomized to receive in addition to own mother´s 
breast milk one of three supplements:  liquid CM formula (Tutteli, Valio, Finland), extensively 
hydrolyzed whey formula (Pepti-Junior, Nutricia, The Netherlands) or donor BM (a mixture of 
BM from multiple donors expressed 1-6 months after delivery) (Saarinen et al. 1999). Of the 
original cohort, 247 infants reportedly developed cow’s milk related symptoms which subsided 
during elimination diet. These infants underwent at mean age 7 months (+/- SD 2) an open 
oral CM challenge, which confirmed CMA in 118 and was negative in 129. We obtained serum 
samples from infants who did not react at CM challenge at this point only, whereas serum 
samples from children who were diagnosed with CMA were available in addition at time points 
one year after diagnosis and in most cases, at follow-up at mean age of 8.6 years (see below). 
 
We considered CMA to be IgE-mediated if skin prick test with CM extract resulted in a wheal 
diameter ≥ 3mm greater the negative control or the level of CM specific IgE antibodies was ≥ 
0.7 kU/L (measured with UniCap, Phadia, Uppsala, Sweden) or both were positive at any time 
point 0-12 months after diagnosis (Saarinen et al. 2005). Of the infants with CMA, 86 (73%) 
had IgE-mediated and 32 (27%) non-IgE-mediated CMA (Saarinen et al. 2005). All 118 
children with CMA were invited to visit an outpatient clinic every 6 months up to age 2 years, 
and annually thereafter until recovery.  Recovery was defined as regular consumption of CM or 






Between August 2003 and March 2004, a follow-up study on patients’ CMA status and other 
atopic manifestations was carried out. Of the invited 118 children with a history of CMA, the 
large majority, 94 (80%) participated. We also invited an equal number of randomly selected 
subjects without CMA from the same cohort (“control subjects”), and 80 (68%) of them 
visited the outpatient clinic (Saarinen et al. 2005). At this time, the children in both groups 
were 8-9 years (mean 8.6 years) old. At the follow-up visit, an investigator carried out a 
structured interview and a physical examination. Skin prick tests (SPTs) were performed with a 
panel of 18 allergens, with standard solutions for most allergens and prick-to-prick method for 
a few food allergens as previously described (Saarinen et al. 2005).  
 
Blood samples were drawn at each visit at the outpatient clinic. Sera were thus available from 
the majority of patients with CMA at diagnosis, a year later and at follow-up (please see below 
for numbers of samples in each study). Serum samples from infants with CM-related 
symptoms but negative CM challenge were available at the time of the diagnostic (negative) 
CM challenge only. DNA and PBMCs were extracted from whole blood samples drawn at the 
follow-up visit.  
 
For study I, blood samples were available from 163 children: 87 patients with CMA and 76 
control subjects. Of the patients in this study, 11 (13%) had persistent CMA, others had 
become tolerant to CM by the time of the follow-up visit. Table 1 in the original publication of 
study I shows the clinical characteristics of the study population. 
For study II, serum samples from the patients were available at diagnosis (mean age 7 
months, n=111), one year later (mean age 19 months, n= 101) and at follow-up (mean age 8.6 
years, n=85); as well as salivary samples (n=107) at diagnosis.  In addition, sera from 80 
control subjects from the same cohort were available at follow-up (mean age 8.6 years). Clinical 
characteristics are shown in Tables 1 and 2 of the original publication II. 
For study III (table 3), serum samples were available from 11 patients who still had active 
IgE-mediated CMA at mean age of 8.6 years, and selected 12 patients who had recovered from 
IgE-mediated CMA by age 3 years. From these patients, we investigated serum samples 
collected at the time of diagnosis, one year later and at the final follow-up (see table 2 for time 
points). The selection criteria for the patients in study IV were: active IgE-mediated CMA at 
age 8.6 years (persisting CMA) or recovery from IgE-mediated CMA by age 3 years (transient 
CMA), and serum samples available at all three time points. Serum samples drawn at follow-up 
from six non-atopic control subjects served as reference. Age, the outcome of an open oral 
cow’s milk challenge and cow’s milk specific IgE levels at three time points in the study groups 





In study IV, we examined PBMC samples from 57 children aged 5-12. The population 
consisted of three groups:  16 had active CMA, 20 had recovered from CMA by age 3 years, 
and 21 were non-atopic control subjects.  The majority of subjects had participated at age 8-9 
years to the study described above (Saarinen et al. 2005).  In addition, we recruited nine 
patients with active CMA beyond age 5 years (range 5.4-12.3) in spring 2008 at the Helsinki 
University Hospital.  CMA diagnosis was based on an open CM oral challenge, and the current 
CMA status on either an oral challenge or regular consumption of CM.  The CMA was or had 
been IgE mediated in all patients.  The control subjects were considered non-atopic based on 
absence of atopic symptoms, total IgE less than 130 kU/l (measured with UniCAP, Phadia, 
Uppsala, Sweden) and negative skin prick tests (SPTs) that were performed with a panel of 18 
allergens, as previously described (Saarinen et al. 2005).   
 
DNA extraction and genotyping 
 
We applied a salting out method for extracting DNA from whole blood samples (Miller, Dykes 
& Polesky 1988) . We defined the common European HLA class II haplotypes using a low 
resolution full-house genotyping method that has been described earlier (Hermann et al. 2003). 
We genotyped the PTPN22 C1858T (rs2476601) polymorphism with a homogeneous 
genotyping (Kiviniemi et al. 2003).   
For analysing five mutations of filaggrin gene (del22824, 501-C/T, R2447X, S3247, 3702delG) 
we used direct sequencing with MegaBACE1000 equipment (GE Healthcare, Amersham 
Biosciences, Piscataway, NJ, USA). The number of analysed samples varied between different 
filaggrin gene polymorphisms: 113 cases (64 patients; 49 control subjects) were studied for 
del22824, 153 (83; 70) for 501-C/T, 96 (52; 44) for R2447X, 118 (62; 56) for S3247 and 111 
(64; 47) for 3702delG.  
All genotyping was performed in professor Ilonen’s group, Department of Clinical 
Microbiology, University of Kuopio, Kuopio, Finland. 
 
Measurement of antibodies  
 
We stored serum samples at -80°C until analyzed.   
We measured the serum total IgE concentration and the allergen-specific IgE antibodies to 
CM, hen’s egg ovalbumin and birch with enzymatic UniCap fluoroimmunoassay (Phadia, 





We measured bovine-β-lactoglobulin and ovabumin specific IgA and IgG levels with enzyme-
linked immunosorbent assays (ELISA) (Savilahti et al. 1993).  Microtiter plates (Nunc Maxi 
Immunoplate, Thermo Fisher Scientific, Roskilde, Denmark) were coated with bovine-β-
lactoglobulin (Sigma-Aldrich, St. Louis, MO) at a concentration of 1 µg/mL, or with 
ovalbumin (Sigma-Aldrich) at a concentration of 2 µg/mL in phosphate buffered saline (PBS). 
Coated plates were incubated for 3 h at 37 °C. After washing with PBS, unspecific binding was 
blocked with 2% sheep serum in PBS. Plates were then incubated for 1 h at 37 °C and washed 
thereafter with PBS-0.05%Tween. Sera were diluted in 1% sheep serum in PBS-0.05% Tween 
and applied in duplicate to the antigen-coated plates and to control plates (coated only with 
blocking solution) at dilutions of 1:20 for β-lactoglobulin  IgA and IgG, or 1:20 for ovalbumin 
IgA and 1:400 for ovalbumin IgG. The plates were incubated overnight at 4 °C. Thereafter the 
plates were washed with 1% PBS-0.05%Tween three times. Alkaline phosphatase-conjugated 
Affine Pure Rabbit anti-human IgA and IgG (Jackson, Baltimore) in a concentration of 0.3 
mg/ml were applied at dilutions of  1:1000 for  β-lactoglobulin  and ovalbumin IgA, and  
1:3000 for β-lactoglobulin  and ovalbumin  IgG. The plates were incubated for 1 h at 37 °C. 
After washings, the substrate 1 mg/ml p-nitrophenyl phosphate in Tris buffer (Sigma-Aldrich, 
St. Louis, MO)was added. After 30 min at 37 °C the reaction was stopped with 1M NaOH. 
The optical density of the end product was immediately measured at 405 nm with a 
semiautomatic photometer (Labsystems Multiscan, Frankfurt, Germany). 
 
Protocol for measuring α-casein specific IgA and IgG levels with ELISA has also been 
described (Savilahti et al. 1993).  Microtiter plates (Nunc Maxi Immunoplate, Thermo Fisher 
Scientific) were coated with bovine-α-casein (Sigma-Aldrich) at a concentration of 2 µg/mL in 
phosphate buffered saline (PBS). Coated plates were incubated for 3 h at 37 °C. After washing 
with Tris-buffered saline (TBS), unspecific binding was blocked with 1% gelatin in TBS. Plates 
were then incubated for 1 h at 37 °C and washed thereafter with TBS- 0,05% Tween. Sera 
were diluted with 1% gelatin in TBS-0,05%- Tween at dilutions of 1:50 for IgA and 1:200  for 
IgG, and applied in duplicate to the antigen-coated plates and to control plates. Plates were 
incubated for 1 h at 37 °C.  Alkaline phosphatase-conjugated Affine Pure Rabbit anti-human 
IgA and IgG (Jackson, Baltimore) in a of concentration 0.3 mg/ml were applied at dilutions of 
1:700 for IgA and 1:6000 for IgG. Thereafter, the protocol continued as for β-lactoglobulin 
and ovalbumin IgA and IgG measurements as described above.  
  
For measuring the levels of IgG1 and IgG4 to β-lactoglobulin and α-casein we adapted ELISA 
protocols from Ruiter et al (Ruiter et al. 2007a). Microtiter plates (Nunc Maxi Immunoplate, 
Thermo Fisher Scientific, Roskilde, Denmark) were coated and blocked as described above.  
Sera were applied on the plates as described above:  at dilutions of 1:20 (for α-casein IgG4, 
BLG IgG4) or 1:100 (for ovalbumin IgG4). The plates were then incubated for 1 h at 37°C. 
After washing, 100 µL of horseradish peroxidase (HRP) conjugated anti-human IgG4 
(Sanquin, Amsterdam, Netherlands) at dilutions of 1:30000 for α-casein and ovalbumin or 





dilution 1:1000 was applied on wells, followed by an incubation of 1 h at 37°C.  After washing, 
100 µL of tetramethyl-benzidine (TMB) liquid substrate (Sigma-Aldrich) was applied on plates 
and incubated for 10 min at room temperature, sheltered from light.  The reaction was stopped 
with 1 M H3PO4. A wavelength of 450 nm was used to immediately measure the optical 
density of the end product with a semiautomatic photometer (Labsystems Multiscan, 
Frankfurt, Germany).  
 
Values of ELISA results were expressed as arbitrary units (AU) deduced from the optical 
densities of the reference serum curve with a high level of antibodies after subtracting the 
blanks.  
 
Peptide microarray based immunoassay 
 
We performed the peptide microassay based immunoassay as previously described 
(Shreffler et al. 2005, Lin et al. 2009) with minor modifications. Commercially synthesized 289 
peptides of 20 amino acids with an offset of 3 amino acids, corresponding to the primary 
sequences of αs1-, αs2-, β-, and κ-caseins, and β-lactoglobulin, (JPT Peptide Technologies 
GmbH, Berlin, Germany) were resuspended in dimethyl sulfoxide (DMSO) at 1 mg/mL, 
diluted 1:2 in Protein Printing Buffer (PPB, TeleChem International, Inc., Sunnyvale, CA, 
USA) with 0.02% Sarkosyl to a final concentration of 0.5 mg/mL. Peptides were printed on 
epoxy-derivatized glass slides (SuperEpoxy Substrate, TeleChem International, Inc.,) using a 
NanoPrint™ Microarrayer 60 (TeleChem International, Inc.) equipped with 2×4 ArrayIt 
Stealth Micro Spotting Pin (SMP3B). Fluorochrome- labelled human serum albumin was 
printed as a reference for the grid and protein printing buffer as a spot negative control for 
background normalization. For immunolabeling, an area around the arrays was demarcated 
with a hydrophobic pen (DakoCytomation Pen, DAKO, Glostrup, Denmark). Incubations 
were performed in the dark in a humidity chamber (Binding Site, Birmingham, UK) on an 
orbital rotating platform with gentle agitation. The day after printing, the slides were washed 
with phosphate-buffered saline containing 0.05% tween 20 (PBS-T) and dH2O. Non-specific 
binding sites were blocked with 400 µl of 1% human serum albumin (HSA) in PBS-T (PBS-
T/HSA) for 60 minutes at 31 o C. After aspiration of blocking buffer, 250 µl of patient serum 
diluted 1:5 in PBS-T/HSA was incubated for 16 hours at 4o C. Slides were then washed with 
PBS-T. 
 
For IgE and IgG4 detection, slides were incubated for 24 hours at 4o C with a cocktail of 
four monoclonal antibodies. Three were monoclonal biotinylated anti-human IgE: one from 
Invitrogen (Carlsbad, CA, USA) and diluted 1:250, one from BD Biosciences (Pharmingen, 
San Jose, CA, USA) and diluted 1:250, and one as a gift from Phadia (Uppsala, Sweden) 
biotinylated in our laboratory and diluted 1:1000. The cocktail further included one 





Birmingham, AL, USA) diluted 1:1000. Slides were subsequently washed with PBS-T, 
incubated for 4 minutes with ethylene diamine tetraacetic acid (EDTA) 1 mM in PBS-T, 
washed again with PBS-T, equilibrated for 1 minute with Dendrimer Buffer (Genisphere, 
Philadelphia, USA) followed by incubation for 3 hours at 31 o C with a cocktail of Anti-Biotin-
Dendrimer_Oyster 550 (350) (Genisphere) and Anti-FITC_Dendrimer_Oyster 650 (350) 
(Genisphere) in Dendrimer Buffer both at 0.6 µg/ml with addition of 0.02 µg/ml of salmon 
sperm DNA. Finally, slides were washed with PBS-T, 15 mM Tris buffer, centrifuge dried, 
followed by wash with 0.1 X PBS, centrifuge dried, washed again with 0.05 X PBS and 
centrifuge dried.  
 
For IgA detection, slides were printed a week before immunolabeling in order to reduce 
background. After serum incubation and washing, slides were incubated for 1 h at 31 o C with 
polyclonal goat anti-human IgA diluted 1: 250 (Sigma-Aldrich) which was covalently 
conjugated with Alexa 546 (Molecular Probes – Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Slides were then washed with PBST, distilled water, and centrifuge 
dried. 
 
Immunolabeled slides were scanned using a ScanArray®Gx (PerkinElmer, Waltham, MA, 
USA). Images were saved as TIF format. The results are semiquantitative. 
 
Image analysis in microarray based immunoassay  
 
We analyzed peptide array chip images for quality control, and quantified the spot intensities as 
the mean of the detected spot area brightness. The local backgrounds of the spots were 
detected and the final normalized value was expressed as 
 
I_n = (I - I_b) / (I_p - I_{pb}) 
 
Where 
I = spot mean intensity 
Ib = spot local background intensity 
Ip = PBSO spots' median intensity (several on each chip) 
Ipb = PBSO spot local background intensity 
 
We calculated a median of the peptide spot intensities on each chip. The intensity was labeled 
as active if the intensity deviated more than half standard deviations from the normalized zero 







PBMC extraction and in vitro stimulation  
 
We extracted PBMCs with Ficoll Paque (GE Healthcare Bio Sciences Corp, Piscataway, NJ) 
centrifugation of heparinized blood samples. The cells were frozen overnight in an isopropanol 
container at -70°C, and stored at -135°C in a medium with 10% dimethyl sulfoxide ((CH3)2SO, 
DMSO ; Sigma Aldrich, St. Louis, MO) and 90% cell culture medium with RPMI 1640 
medium with 25 mM Hepes (Gibco Invitrogen, Carlsbad, CA) containing 5% human AB 
serum (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland),  2 mM L-glutamine 
(Gibco) and 25 µg/ml gentamycin (Sigma Aldrich).  Before in vitro stimulation, samples were 
thawn briefly in +37°C water bath, suspended in RPMI 1640 medium with 25 mM Hepes 
(Gibco) and centrifuged at 1100 g for 10 min to wash out the DMSO.  The RPMI medium was 
removed and cells were suspended in cell culture medium described above. Median cell 
recovery after thawing was 70-77% in the three study groups.  
 
Immediately after thawing PBMCs were stimulated in vitro with bovine β-lactoglobulin (Sigma 
Aldrich) at a concentration of 200 µg/ml in cell culture medium described above. We 
confirmed the purity of the  β-lactoglobulin with FPLC. Sterile PBS (Biowhittaker Lonza, 
Basel, Switzerland) served as negative control, and tetanus toxoid (National Public Health 
Institute, Helsinki, Finland) at a concentration of 16 µg/ml was the positive control whenever 
cells sufficed for all three stimulations. Cells were cultured at + 37°C, with 5% CO2.  For RNA 
extraction, PBMCs were cultured for 72 h in 96 well plates (Corning Life Sciences, Corning, 
NY), 0.2 million cells per well and a total of 1.2 million cells per antigen stimulation. For flow 
cytometry, PBMCs were cultured for 120h in 48 well plates (Greiner Bio-One, 
Kremsmuenster, Austria), 0.5 million cells per well and a total of 2-4 million cells per antigen 
stimulation, depending on the amount of cells available. The culture times for RNA extraction 
and protein expression had been optimized previously (Marschan et al. 2008), and they are 
consistent with work by other groups (e.g. (Savolainen et al. 2007). 
 
RNA extraction and reverse transcription 
 
We harvested PBMCs after 72h of stimulation. Wells were washed twice with sterile PBS 
(Biowhittaker Lonza ), and cells spinned at 1100 g for 10 min. We suspended cell pellets in 
RNeasy Minikit lysis buffer (Qiagen, Hilden, Germany) with 1% mercaptoethanol, and 
incubated at room temperature for 3-5 min. We stored cell lysates and cell culture supernatants 
at -70°C. After thawing in room temperature, we spinned cell lysates through QiaShredder 
columns (Qiagen,) following manufacturer’s instructions. We extracted RNA with Qiagen 
RNeasy Minikit according to manufacturer’s instructions with the optional DNAse step added 
(Qiagen RNAse-free DNAse I set) in order to remove genomic DNA. We measured RNA 





MA). RNA was reverse transcribed with TaqMan Reverse Transcription reagents (Applied 
Biosystems, Foster City, CA, USA).  RNA was stored at -70°C and cDNA at -20°C. 
 
Real time polymerase chain reaction (QRT-PCR) 
 
We ran complementary-DNA samples in triplicates on StepOne QRT-PCR system (Applied 
Biosystems) with TaqMan reagents (Applied Biosystems ) using FAM labeled probes and ROX 
as passive reference.  We selected 12 gene expression markers based on recent literature on 
Treg function. Target specific primers for T-bet, GATA-3, IFN-γ, CTLA4, IL-10, IL-16, TGF-
β, FoxP3, Nfat-C2, TIM3, TIM4, STIM-1 and 18s were purchased from Applied Biosystems. 
Ribosomal 18S RNA served as an endogenous control. The sequence detector (Stepone plus 
real-time PCR systems, Applied Biosystems) was programmed for an initial step of 20 seconds 
at 95oC, followed by 40 thermal cycles of 1 second at 95oC and 20 seconds at 60oC.  
We calculated levels of target gene expression with a comparative threshold cycle (Ct) method 
(as recommended by Applied Biosystems). Normalised samples were calibrated with an inter-
assay standard: an exogenous cDNA pool generated from PHA stimulated PBMCs. The 
relative amount of a target gene in a sample was normalized in relation to both the calibrator 
and to an endogenous control (18S). When ΔCt stands for the difference between Ct of the 
marker gene and Ct of the 18S gene, ΔΔCt denotes the difference between the ΔCt of the 
analyzed sample and ΔCt of the calibrator. Calculation of 2-ΔΔCt then gives a relative amount of 
the target gene in analyzed sample compared with the calibrator, both normalized to an 




We collected PBMCs for flow cytometry after 120h antigen stimulation, and suspended them 
in 0.5% BSA-PBS.  We followed a protocol described earlier (Liu et al. 2006) with a few 
modifications, and performed intracellular staining with Alexa-488-conjugated anti-FoxP3 kit 
by BioLegend (San Diego, CA, USA). Cells were first stained with surface markers for 30 min 
at +4°C. The anti-human antibodies PE-conjugated anti-CD127, APC-conjugated anti-CD25, 
and PerCP-conjugated anti-CD4 as well as appropriate isotype controls were purchased from 
Becton Dickinson (BD Biosciences, San Jose, CA, USA). After washing once with 0.5% BSA-
PBS, cells were fixed for 30 min at RT using 1 x Fix/Perm buffer provided in the kit.  Cells 
were then washed once with 0.5% BSA-PBS and twice with 1x Perm buffer, and blocked with 
mouse IgG for 15 min at RT. Anti-human Alexa-488-conjugated FoxP3 was added, and cells 
were stained for 30 min at +4°C. After washing twice with 1x Perm buffer, cells were 





cell samples were run on FACS Calibur (BD Biosciences), and analyzed with BD FACSDiva 




In study I, the HLA haplotypes as well as PTPN22 and filaggrin alleles were coded 
dichotomically as present or absent. We tested differences in the distribution of alleles between 
groups with Fisher’s exact test. Logarithmic transformations of antibody levels (IgA, IgG, 
IgG1, IgG4 to whole cow milk, α-casein, bovine lactoglobulin and ovalbumin, IgE to cow 
milk, hen’s egg  and birch) were compared with the t-test of independent variables between 
allele carriers and  non-carriers among all subjects and within subgroups of control subjects, all 
patients with CMA, and patients with IgE- mediated CMA.  We considered a p-value of 0.003 
or less to be statistically significant, which was based on dividing 0.05 with the number of HLA 
haplotypes analyzed (n=14).  
In study II, we tested differences in the distribution of clinical characteristics in the two patient 
groups with Fisher’s exact test. Logarithmic transformations of antibody levels (IgA, IgG, 
IgG4, IgG1 to CM, α-casein, β-lactoglobulin and ovalbumin, IgE to CM, ovalbumin and birch) 
were compared between the two patient groups (“early tolerant” and “persisting CMA”) and 
between patient groups and control subjects with the t-test of independent variables. We used 
general linear model for repeated measures to test whether antibody levels changed 
significantly over time and also to test whether the profiles of development of antibody levels 
over time differed between different groups. Spearman correlation was calculated for specific 
IgA levels in serum and salivary samples.  
 
In study IV, we compared data of flow cytometry assays, and of the QRT-PCR markers 
selected based on neural network analysis (see below) between the three study groups 
(persisting CMA, recovered CMA and control) with Kruskall-Wallis non-parametric test and 
pairwise with Mann-Whitney test.  
In studies II-II and IV, we considered a p-value of 0.05 or less statistically significant.  
We performed the statistical analyses with SPSS 15.0.1. 
 
Bioinformatic analysis in study III 
 
To find active peptide regions within a sample group, the active peptide hits were convoluted 
with a gaussian curve of <m>\sigma=2</m>. Smoothed activation values were averaged 





smooothed averages. A peptide region was labeled active if within it an active peptide was 
detected in at least half of the patients in a group. 
 
We applied decision tree analysis for peptide microarray data from samples at diagnosis in 
order to investigate whether a set of peptides could classify patients correctly and thus predict 
the clinical pace of recovery from CMA. Peptide binding by IgE, IgG4 and IgA was coded 
dichotomously as active or absent. Since building classifier for 289 (the number of peptides in 
the microarray) attributes and 23 samples failed to give meaningful classification results, we 
applied attribute selection algorithm that considers attribute relevance and redundancy (Lei, 
Huan 2003). Attribute selection was performed with different datasets and each dataset was 
classified with Random Tree classifier to evaluate which set of attributes best separate cases of 
the two study groups, and to find a classifier. Random Tree builds a decision tree by 
considering randomly chosen log2(n)+1 attributes in each node where n is number of 
attributes. For attribute selection and classification, we used algorithms implemented in Weka-
software (Witten, Frank 2005). 
 
Artificial neural network analysis  
 
In study IV for optimal, distinctive profiling of patient groups, we applied artificial neural 
networks with exhaustive search for all gene marker combinations.  
A multi-layer perceptron (MLP) artificial neural network is a supervised machine learning 
method that mimics biological neural networks. Structurally, MLPs comprise nodes that are 
ordered into input, hidden and output layers, and arcs that propagated signals from nodes in 
input layer to nodes hidden layer as well as nodes from hidden layer to output layer (Bishop 
1995). Each node in a hidden and output layer has an activation function that transforms the 
incoming signals to a single value that is further propagated to the connected nodes in the next 
layer. Arcs are associated with weight values that are modified during the training stage in 
which the classifier is built. 
We evaluated classifier performances with five-fold-cross-validation using three different 
means to assess the performance. First, we used confusion matrix, which presents the 
distribution of classification results in matrix form where the columns are real classes and the 
rows are predicted classes. Second, we used the kappa-value that describes how much the 
agreement on classification results differs from random guessing (Fleiss 1971). Kappa-statistics 
is calculated as (Po - Pc)/(1 - Pc), where Po is the observed agreement and Pc is the agreement 
that would be achieved by chance. For a perfect classification, kappa-value is one and the value 
of zero means classification expected by chance. 
The third statistical validation method we employed is a receiver operating characteristic 





for each class, the true-positive rate is plotted against the false-positive rate (Fawcett 2006). . 
Area under ROC curve (AUC) is the value that describes the size of the area that the curve 
occupies from the graph. For a perfect classification, the AUC value is one, whereas random 
guess produces is the AUC value of 0.5. 
We created all 4095 marker combinations from the 12 markers (212-1) and trained 4095 
classifiers using the delta Ct transformed β-lactoglobulin stimulated expression marker 
combinations. Classifiers were built with the MP-algorithm in Weka data mining software 
(Witten, Frank 2005).Number of layers, neurons and connections were automatically chosen 
by the MP-algorithm as follows. One input and output neuron for each of three classes and 
(number of markers + number of classes)/2 neurons in one hidden layer. In Weka, kappa-
statistics is calculated from the values in the confusion matrix and the result presents the 
agreement between true and predicted classes. We compared the validation results using 








Association of selected genetic factors with humoral responses to early 
food allergens (I) 
 
We did not find any association between CMA and the genetic factors we investigated. The 14 
HLA haplotypes were similarly distributed among control subjects and patients with CMA or 
with IgE-mediated CMA (study I, Table 2).  
 
Neither did we observe any difference in the distribution of the PTPN22 polymorphism 
C1858T (rs2476601) between these groups (data not shown).  Six subjects were heterozygote 
carriers of the filaggrin null mutation del22824: 3 patients with CMA (3/87) and 3 control 
subjects (3/76).   All three control subjects carrying the filaggrin del22824 mutation had 
reported allergic symptoms: eczema (n=3), allergic rhino-conjuctivitis (n=2) or asthma (n=1), 
and one of them had positive SPT to aeroallergens.  The three carriers with IgE-mediated 
CMA had eczema. The other four filaggrin mutations screened were absent in the study 
population.  
 
In spite of no association with CMA, humoral responses to CM and hen’s egg antigens were 
associated with two HLA II haplotypes (study I, Table 3, Fig 1 and 2).  Data for the entire 
study population is depicted in Table 1, whereas Figures 1 and 2 show the data divided by 
subgroups of control subjects, all patients with CMA and patients with IgE-mediated CMA.  
 
Carriers of (DR15)-DQB1*0602 had higher IgG and IgG4 levels to bovine β-lactoglobulin and 
α-casein than non-carriers (study I, Table 3). In patients with CMA, the association was 
significant for both bovine β-lactoglobulin and α-casein, whereas no difference was seen in the 
control group (study I, Fig 1). Specific IgG1 to all antigens tested were on comparable levels 
among (DR15)-DQB1*0602 carriers and non-carriers (data not shown). 
 
Unlike with (DR15)-DQB1*0602, lower antibody levels to β-lactoglobulin and ovalbumin were 
associated with (DR1/10)-DQB1*0501 (study I, Table 3, Fig 2). Depending on the antibody 
subclass and the allergen, the differences were present among either control subjects or 
patients with CMA (study I, Fig 2). The difference in IgG1 levels to ovalbumin nearly reached 
significance (t-test p-value 0.005) between control subjects with the DQB1*0501 allele (n=29; 
geometric mean 12 AU; 95% CI 6.3-22) and without the allele (n=47; geometric mean 36 AU; 






We further compared carriers of (DR15)-DQB1*0602 with those of either of (DR1/10)-
DQB1*0501 (study I, Table 3). Carriers of (DR15)-DQB1*0602 had higher IgG and IgG4 
levels to β-lactoglobulin as well as higher IgG, IgG4 and IgG1 levels to ovalbumin than 
carriers of (DR1/10)-DQB1*0501 (study I, Table 3). In the comparison within subgroups, the 
differences were significant among CMA patients and only suggestive among control subjects 
(data not shown). 
 
 None of the genetic factors investigated was associated with IgA and IgE levels to the early 
food allergens (data not shown). A suggestive association was found between haplotype 
(DR9)-DQA1*03-DQB1*0303 and higher IgE levels to birch (allele carriers n=6; geometric 
mean 4.038 kU A/l; 95% CI 0.488-33.395 vs. non-carriers n=132; geometric mean 0.182; 95% 
CI 0.116-0.286; t-test p-value 0.006). Filaggrin gene deletion at 22824 was associated with 
lower IgE levels to cow’s milk but the association did not, however, reach statistical 
significance (allele carriers n=6; geometric mean 0.048 kU A/l; 95% CI 0.026-0.091 vs. non-
carriers n=113; geometric mean 0.161 AU; 95% CI 0.125-0.209; t-test p-value 0.039). 
 
Development of  humoral responses to cow’s milk proteins in patients with 
CMA over time and differences compared to children without CMA  at 
follow-up (II-III) 
 
We investigated differences in specific antibody levels to CM proteins and in CM epitope 
binding by antibodies between patients who had recovered early and those with persisting 
CMA. Please refer to method section “study population” for characteristics and number of 
subjects in the study groups these data are based on. 
Levels of specific IgE to CM evolved differently in patients with persisting CMA and 
patients with early recovery (II) 
 
Children with persisting CMA at age 8 years had higher levels of CM specific IgE at all three 
time points compared with those who became tolerant by age 3 years (Fig 3 and study II, Table 
3,). General linear model (GLM) of repeated measures indicated that both time (p<0.001) and 
group (II, Table 4; p=0.005) were significant factors.   At follow-up, levels of CM specific IgE 
were higher in all children who had a history of IgE-mediated CMA, including those with early 
recovery, compared with control subjects (II, Table 3).  
Figure 3. Levels of cow’s milk (CM) specific IgE in 2 groups: patients who recovered from 





years (checkered boxes). The y-axis represents IgE levels to CM in kU/L. Measurements are 
shown on a log10 scale; lines mark (from bottom up) the 5th percentile, lower quartile, median, 
upper quartile and the 95th percentile. The x-axis depicts the 3 time points under investigation: 
at diagnosis (dg), one year after (dg +1y) and at follow-up. An asterix denotes a p-value < 
0.0001 based on the t-test of independent variables.  
 
 
Patients with persisting CMA had more intense and stable IgE peptide binding over 
time than patients with early recovery (III) 
 
At diagnosis, IgE binding pattern to CM peptides in both patient groups differed little (III, Fig 
1A). The persisting group had more intense IgE binding than early tolerant to one region on β-
casein, three regions in β –lactoglobulin and one wide region on κ-casein (III, Fig 1A). The 
recognition profile of children with persisting CMA did not change over time (study III, Fig 1). 
The signal overall was strongest at the time of diagnosis, except for a region in αs2-casein 
which gave a stronger signal at follow-up than at earlier time points (study III, Fig 1E). In 
contrast, IgE from patients developing early tolerance recognized fewer peptides over time 
(III, Fig 1A-D, Table II) except for an increased signal at follow-up in a region of κ-casein (III, 
Fig 1C-D). At follow-up, IgE from patients with persisting CMA bound to a large region 
within all five proteins (III, Fig 1C). 
Comparing the differences in IgE binding between the time of diagnosis and one year later or 
at final follow-up, the binding increased in regions of αs1- and αs2-caseins more in patients 
with persisting CMA than in patients with early recovery (III, Fig 1D-E). The opposite was 
observed for β-casein, β-lactoglobulin and κ-casein (III, Fig 1D-E). 
Patients with persisting CMA had lower IgG4 levels to β-lactoglobulin at follow-up than 
patients with early recovery (II) 
 
In contrast to CM specific IgE levels, serum IgG4 levels to β-lactoglobulin were lower at 
follow-up among patients with persistent CMA at age 8 years than among patients tolerating 





Comparison of serum IgG4 levels to α-casein resulted in similar, although less pronounced, 
differences between groups (II, Table 4).  Time and group were both significant factors to 
differences in temporal profiles of β-lactoglobulin IgG4 levels (GLM of repeated measures: 
p<0.01): the levels increased more over time among patients who became tolerant by age 3 
years than among those with persistent CMA at age 8 years (II, Fig 1a). Levels of IgG1 to β-
lactoglobulin and α-casein did not differ between the groups (data not shown).  
IgG4 peptide binding patterns were comparable in persisting and early recovering CMA 
(III) 
 
Patients with persisting CMA and those with early recovery had similar IgG4 binding patterns 
at diagnosis, whereas the signal in persisting CMA was more intense (III, Fig 2A). Wide regions 
especially in αs1-casein and β-casein remained unrecognized (III, Fig 2A). Differences emerged 
mostly from the two groups recognizing different regions located very close to each other on 
the same protein (III, Fig 2A). There was, however, a region in β-casein that patients with 
persisting CMA recognized but those with early recovery did not (III, Fig 2A); the difference 
was similar with IgE recognition in the same region (III, Fig 1A). The IgG4 binding profiles 
changed little over time, whereas the binding signal increased (III, Fig 2A-E, Table II). At 
follow-up, patients with persisting CMA bound more peptides in αs1-casein and β-casein, and 
patients with early recovery in one region of β—lactoglobulin and one of κ-casein; binding 
decreased at the terminal end of κ -casein (III, Fig 2C). Comparing the changes in IgG4 
binding between time of diagnosis and one year after or follow-up, no clear pattern could be 
observed in differences between the groups (III, Fig 2E-D).  
IgE and IgG4 binding to a panel of peptides at diagnosis discerned patients with 
persisting CMA from patients recovering early (III) 
 
Random decision tree analysis showed that IgE and IgG4 binding to a panel of regions in αs1-, 
αs2-, β-and κ-casein (III, Table III) categorized the two patient groups at the time of diagnosis 
with significant accuracy (area under curve AUC 92%, κ-statistic 0.87). This classification for 
separating patients with persistent CMA from patients that recovered early from CMA had a 
sensitivity of 96% and specificity of 91%. We included CM IgE level (measured with UniCAP) 
as a variable to the dataset before and after the feature selection step, but the prediction 
accuracy did not improve (data not shown).  
β-lactoglobulin specific IgA levels were higher in patients with early recovery (II) 
 
Serum levels of IgA to β-lactoglobulin were higher at the time of diagnosis in patients who 
recovered from CMA by 3 years compared with both groups where recovery was delayed until 
either 3-8 years or beyond 8 years (II, Fig 1b, Table 4). Analysis with general linear model 





trend over time (II, Fig 1b), whereas the temporal profiles of specific IgA levels did not differ 
significantly between the groups.  
In patients who recovered from CMA by age 3 years, serum β-lactoglobulin specific IgA levels 
correlated positively with salivary CM specific IgA levels at diagnosis (Spearman correlation 
coefficient 0.4; n=53; p<0.005) and a year later (Spearman correlation coefficient 0.4; 
n=52; p<0.03).  Patients who recovered by age 8 years showed the same association 
(Spearman correlation coefficient at diagnosis 0.4; n=63, and a year later 0.3; n=61; for 
both p<0.001), but not patients with persistent CMA at age 8 years (Spearman correlation 
coefficient at diagnosis 0.4; n=16; p=0.2 and a year later -0.04; n=14; p=0.9). 
IgA binding to CM epitopes increased over time more in patients with persisting CMA 
(III) 
 
IgA binding to CM epitopes measured with the microarray based immunoassay was overall 
low. It increased, however, at follow-up especially in patients with persisting CMA compared 
with earlier time points (III, Fig 3B). At follow-up, both patient groups had binding with high 
signal intensity at the terminal end of αs2-casein (III, Fig 3A). The recognition profiles were 
similar in the two groups, except for two regions in β-casein that persisting CMA group 
showed more signal intensity in IgA binding than the group with early recovery (III, Fig 3). 
Comparing the changes in IgA binding between time of diagnosis and one year after, signal 
intensity in the two groups did not differ. By follow-up, however, the intensity of IgA binding 
increased more in patients with persisting CMA in several regions across all five proteins (III, 
Fig 3).  
Peptide recognition by IgE had overlap with IgG4, but not with IgA (III) 
 
Peptide binding pattern of IgG4 antibodies was similar to that of IgE in both groups (III, Fig 
1, Fig 2, Fig E6, Fig E7). 
Among patients with early recovery, IgE binding decreased over time while IgG4 binding 
remained at same level, or increased in some regions by follow-up (III, Table 2). Among 
patients with persisting CMA, the signal intensity of IgE binding remained as strong as or 
became stronger than that of IgG4 binding, apart from regions in β-casein (III, Fig 4A). The 
difference between IgE binding intensity and that of IgG4 was stronger in the patient with 
persisting CMA compared than with patients with early recovery at time points after diagnosis, 
primarily in regions of αs1- and αs2-caseins (III, Fig 4A).  
The peptide binding profiles of IgE and IgA had little overlap in αs1- and αs2-caseins in either 
group, a little more in β-casein, β-lactoglobulin and κ-casein (III, Fig 1C, Fig 3A, Fig 4B). The 
differences between IgE binding intensity and that of IgA were larger in patients with 
persisting CMA compared with patients with early recovery at diagnosis and one year after in 





binding existed in these regions (data not shown).  At follow-up, the differences were in 
contrast smaller in patients with persisting CMA compared with patients with early recovery in 
regions of αs2- and β-casein, β-lactoglobulin and κ-casein (III, Fig 4B). 
 
Summary of differences in specific antibody responses between patients 
with persisting CMA and those with early recovery (II-III) 
 
Table 3. Summary of findings in studies II and III. P denotes patients with CMA persisting 
beyond the age of 8 years and E denotes patients with recovery from CMA by the age of 3 
years. CM stands for cow’s milk and BLG for β-lactoglobulin 
 
CM specific IgE levels over time P > E 
CM epitope binding by IgE over time P > E 
BLG specific IgG4 levels at age 8-9 years P < E 
CM epitope binding by IgG4 P ~ E 
BLG specific IgA levels at diagnosis P < E 
CM epitope binding by IgA over time P > E 
CM epitope binding by IgE in relation to 
binding by IgG4 






T regulatory cell and Th2 expression profile in children with CMA (IV) 
 
We studied the response to β-lactoglobulin in vitro by stimulating PBMCs from patients with 
persisting CMA and those who had recovered from CMA by age 3 years. We investigated the 
subsequent expression of protein markers identifying Tregs with flow cytometry, and of RNA 
markers related to Treg and Th2 functions with QRT-PCR. 
 
In the flow cytometry assay, FoxP3 expression intensity in CD4+ CD25highCD127low cells was 
higher in β-lactoglobulin stimulated PBMCs from children with persisting or recovered CMA 
compared with non-atopic children (IV, Table 1, Kruskall-Wallis test p-value <0.05, pairwise 
testing Mann-Whitney p-values < 0.05). FoxP3 expression intensity in children with persisting 
or recovered CMA was comparable (IV, Table 1, Mann-Whitney p-value > 0.5). The 
percentage of CD25highCD127low cells in CD4+ cells or the percentage of FoxP3+ cells in CD4 
+ CD25highCD127low cells did not differ between the groups (IV, Table 1).  
 
We analyzed the QRT-PCR data of 12 marker (T-bet, GATA-3, IFN-γ, CTLA4, IL-10, IL-16, 
TGF-β, FoxP3, Nfat-C2, TIM3, TIM4, STIM-1) expression in three study groups with artificial 
neural network analysis with exhaustive search for all marker combinations. The combination 
of QRT-PCR markers FoxP3, IL-16,Nfat-C2,GATA-3 distinguished most accurately patients 
with persisting CMA from patients who recovered early and from non-atopic subjects (IV, 
Table 2). Patients who had recovered early from CMA and non-atopic subjects were less 
discernable (IV, Table 2). FoxP3 RNA expression level was higher in β-lactoglobulin 
stimulated PBMCs from children with persisting CMA than from non-atopic children (IV, 
Table 3, Kruskall-Wallis test p-value <0.02, pairwise testing Mann-Whitney p-value <0.005). 
The difference between children with recovered CMA or with persisting CMA was suggestive 
(IV, Table 3, Mann-Whitney test p-value <0.07); children with recovered CMA and non-atopic 
controls showed no difference (IV, Table 2, Mann-Whitney p-value >0.4).  Expression levels 
of the other three markers did not differ statistically significantly between groups (IV, Table 3, 







Genetic factors modulating the immune responses to early oral antigens 
 
Atopy has an undisputable hereditary component, but the genetic background is multifactorial 
and in complex interaction with environmental factors (Steinke, Rich & Borish 2008). Studies 
have reported, nonetheless, associations between HLA II haplotypes and food allergies 
(Howell et al. 1998, Howell et al. 1998, Boehncke et al. 1998); also a small study has purported 
an association of CMA with HLA-DQ7 (HLA-DQB1*0301) (Camponeschi et al. 1997). 
Considering the complexity of genetics in allergy, it is not surprising that we did not find any 
association between CMA and HLA haplotypes, which confirmed results from a previous 
study (Verkasalo et al. 1983). Indeed, immune responses in CMA are usually mounted to 
several CM proteins (Wal 2004)  and further to a large array of peptides of a single antigen 
(Cerecedo et al. 2008). Studies have demonstrated that antibodies to HLA-DR, HLA-DQ and 
HLA-DP could restrict the proliferation of CM specific T cell clones from CMA patients 
(Inoue et al. 2001, Ruiter et al. 2007b).  Several antigen presenting HLA molecules thus appear 
to be of importance in CMA.   
 
Only one (del22824) of the five filaggrin mutations tested was present in three patients with 
CMA and three control subjects, who all had manifestations of atopy. Since the filaggrin 
mutation was evenly distributed between patients with CMA and control subjects, our results 
do not support the proposition that topical exposure to CM antigens through disrupted skin 
barrier would initiate CMA (Hsieh et al. 2003, Weidinger et al. 2006).   Our results did conform 
to the notion that filaggrin mutations associate with atopic dermatitis and with atopic disorders 
more broadly (Brown et al. 2008, O'Regan et al. 2009, van den Oord, Sheikh 2009, Palmer et 
al. 2006). On the other hand, filaggrin has been reported to have a recessive inheritance 
(Brown et al. 2008), whereas our study subjects were heterozygous carriers of the del22824 
mutation. In regard to the R620W allele of the PTPN22, we found no association with CMA, 
or with antibody levels to CM antigens and ovalbumin. This is in agreement with results that 
PTPN22 polymorphism is associated with autoimmune diseases, not atopy (Maier et al. 2006)  
or asthma (Majorczyk et al. 2007). 
 
We found a novel association between HLA II haplotypes and humoral responses to early oral 
antigens. HLA (DR15)-DQB1*0602 haplotype in patients with CMA was associated with high 
IgG and IgG4 levels to β-lactoglobulin and α-casein. In contrast, (DR1/10)-DQB1*0501 was 
associated, in particular among control subjects, with low IgG and IgG4 levels to the CM 
antigens, and to ovalbumin. Given the tolerogenic nature of specific IgG4 antibodies (Nouri-





2007a), we speculate that  (DR15)-DQB1*0602 carriers could develop tolerance more 
efficiently in case they are sensitized.  Since the association was observed only in patients with 
CMA, (DR15)-DQB1*0602 appears to have a discernible effect on the antibody response in 
the context of sensitization. Consequently, (DR15)-DQB1*0602 is likely to assert the 
modulating effect through other mechanisms than its peptide-binding properties. One 
hypothetical mechanism would be increase in IFN-γ response, which has been associated with 
(DR15)-DQB1*0602 in humans (Ovsyannikova et al. 2005, Wallden et al. 2008), and in 
transgenic mice (Mangalam et al. 2008). A caveat in interpreting the observed phenomena is 
that since DR and DQ alleles are in strong linkage disequilibriums, the result on  (DR15)-
DQB1*0602 may as well be associated with DR15 molecule encoded by DRB1*1501 and non-
polymorphic DRA1 gene or DR51 molecule encoded by DRB5 and DRA1 genes. 
 
With the HLA DQ molecule containing the DQB1*0501 chain (or DR1 molecule usually 
found with this DQ specificity), we observed an association nearly opposite to the (DR15)-
DQB1*0602 haplotype. Again, the mechanism behind weaker humoral responses to CM 
antigens and ovalbumin in DQB1*0501 carriers is elusive. Our observations are, nonetheless, 
supported by the fact that the associations with different levels of IgG class responses to food 
antigens were present both when comparing separately carriers and non-carriers of either 
haplotypes, and in the comparison between carriers of these haplotypes.  
 
Antibodies in fostering or impeding oral tolerance  
 
We showed that high CM specific IgE levels predict the persistence of CMA, and in case of 
persistence, levels remain high over time. This is in agreement with previous studies (Garcia-
Ara et al. 2004, Vanto et al. 2004, Skripak et al. 2007, Sicherer, Sampson 1999).  The 
observation is further enforced by our results showing that epitope binding by IgE remains 
stable over time in patients with persisting CMA. Our results also corroborate reports that a 
wider IgE epitope profile is associated with persisting CMA (Vila et al. 2001, Cerecedo et al. 
2008). This may reflect the maturation of B cell clones, which results in higher specificity and 
variety of IgE antibodies to CM antigens (Christensen et al. 2008, McHeyzer-Williams, 
McHeyzer-Williams 2005).  
 
We observed that at diagnosis CM epitope binding patterns by IgE were similar in both 
patients with persisting CMA and those with early recovery. Our prospective data thus does 
not support previous reports, based on retrospective settings, which have suggested that IgE 
epitope profiling clearly distinguishes patients with persistent or transient CMA (Vila et al. 
2001, Cerecedo et al. 2008, Wang et al. 2010) . We did identify a few regions in β-casein, β –





persisting CMA than of patients with early recovery. A previous study reported that IgE 
binding of regions in these proteins differentiated patients with active CMA at age 2 years from 
those who had become tolerant by that age (Cerecedo et al. 2008). Contrary to previous 
reports (Vila et al. 2001, Cerecedo et al. 2008, Jarvinen et al. 2002), we observed no difference 
between patient groups in IgE binding of α-casein epitopes at the time of diagnosis. The 
decision tree analysis, however, revealed that combining IgE and IgG4 binding data on a 
relatively small number of regions in αs1-, αs2-, β-and κ-casein predicted with significant 
accuracy, at the time of diagnosis, whether a patient would recover from CMA early or have a 
persisting allergy. Validation in another patient population is required before the prognostic 
value of this result can be adequately assessed.  
 
We found several clues to enforce the notion that IgG subclass antibodies promote tolerance 
rather than allergy. In the comparison of different diagnostic groups at mean age 7 months, 
children who passed an oral CM challenge without symptoms and those who were diagnosed 
with non-IgE-mediated CMA had higher levels of IgG, IgG1 and IgG4 antibodies to CM 
proteins than children with IgE-mediated CMA. Children who recovered early from CMA had 
higher specific IgG4 and lower specific IgE levels to CM proteins at mean age 8.6 years than 
children with persisting CMA. The observation is in line with previous studies on both natural 
tolerance induction in food allergy (Lemon-Mule et al. 2008, Tomicic et al. 2008) and on 
tolerance induced by specific immunotherapy with aeroallergens (Nouri-Aria et al. 2004, 
Francis et al. 2008, Bussmann et al. 2007) as well as desensitization during cow’s milk 
immunotherapy (Skripak et al. 2008).  Higher specific IgG4 levels in patients with early 
recovery may also partly result from regular exposure to CM since it is often included in the 
diet after the patient begins to tolerate CM.  Nevertheless, our findings support the role of 
specific IgG4 antibodies in the maintenance of oral tolerance (Ruiter et al. 2007a) since β-
lactoglobulin and α-casein specific IgG4 levels were increased still years after the patients had 
recovered from CMA, while their CM specific IgE levels remained elevated compared with 
control subjects.   
 
In addition to higher levels of specific IgG4 to both CM protein fractions studied, early 
recovery was associated with increasing IgG4 binding and decreasing IgE binding to 
overlapping CM epitope regions. This conforms to the paradigm that IgG4 acts as a “blocking 
antibody” (Nouri-Aria et al. 2004, van Neerven et al. 1999, Wachholz et al. 2003). 
 
Interestingly, our study showed higher specific IgG4 levels to CM proteins at mean age 7 
months in infants who had received CM formula during the first days after birth and who later 
developed CMA. This plausibly reflects an intense h2 skewing, since Th2 cytokines induce the 
production of both IgG4 and IgE (Punnonen et al. 1993). It also exemplifies an earlier 





antibodies after CM exposure (Lilja et al. 1991). That these infants developed CMA despite 
relatively high IgG4 levels suggests that the balance between IgG4 and IgE was unfavourable 
for tolerance induction. Possibly the IgG4 production was only a side-product of Th2 
activation, and IL-10 production by T regs was not sufficient to switch IgE production more 
towards IgG4 production(Nouri-Aria et al. 2004, Francis et al. 2008). Furthermore, children 
who had received CM at maternity hospital and developed CMA had higher specific IgA levels 
than other feeding groups within children with CMA. Our data thus suggests that early 
exposure to CM in children predisposed to develop CMA induces an overall elevated humoral 
response, where nonetheless IgE response overrides tolerance promoting IgG4 and IgA 
responses. 
 
The association of specific IgA with tolerance is less established compared with IgG4. 
Increasing levels of allergen specific IgA or IgA2 have been reported during successful 
immunotherapy (Francis et al. 2008, Pilette et al. 2007, Scadding et al. 2010). We found that at 
diagnosis, patients whose CMA persisted beyond age 8 years had lower specific IgA levels to 
CM proteins than children who recovered by age 3 years. Specific IgA thus appears to have a 
role in spontaneous development of tolerance. The fact that epitope binding by IgA did not 
overlap with IgE binding conforms to the notion that IgA does not promote tolerance by 
blocking IgE binding like IgG4 does (van Neerven et al. 1999, Pilette et al. 2007).   
 
The relationship between circulating and secretory IgA is of crucial importance since the 
primary function of IgA is on the mucosal surface. We found that β-lactoglobulin specific IgA 
levels in serum correlated positively with salivary levels of CM specific IgA at diagnosis in 
patients who became tolerant to CM by age 3 years. Our results suggest that not only are the 
specific, circulating IgA levels higher in patients who recover early, they also have in 
correlation more secretory IgA to promote tolerance on mucosal surfaces in the gut. These 
findings further question previous reports that have suggested differential production of serum 
and secretory specific IgA antibodies in allergy. In a mouse model of food allergy, tolerance 
to β-lactoglobulin was associated with higher levels of antigen-specific secretory IgA in feces, 
but lower serum levels of specific IgA  (Frossard, Hauser & Eigenmann 2004). A study on 
human subjects either with pollen allergy or with no atopy showed difference in  the antigen 
moieties recognized by serum IgA and those recognized by secretory IgA in tears (Aghayan-
Ugurluoglu et al. 2000).  
 
Differences in specific IgA and IgG4 levels between persisting CMA and CMA that recedes 
early appeared at different time points, which may reflect the mechanisms and regulation of 
IgA and IgG4 in tolerance. The difference between patient groups in specific serum IgA levels 
was seen at diagnosis (mean age 7 months), whereas the difference in IgG4 levels was not 
observed until follow-up at mean age 8.6 years. The regulation of specific IgA production 
appears to be independent of T helper cells (Meiler et al. 2008a), in contrast to IgG4 





2008, Punnonen et al. 1993). Production of specific IgA appears to be associated with local 
TGF-β expression and to induce IL-10 production from monocytes (Pilette et al. 2007). Since 
IL-10 induces IgG4 production (Meiler et al. 2008b), the marching order of IgA increasing 
before IgG4 levels seems logical. Indeed, IL-10 production reportedly increased during grass 
pollen immunotherapy earlier than specific IgG4 levels (Francis et al. 2008).  
 
Furthermore, the mechanism of anti-inflammatory function differs between serum IgA and 
IgG4. Specific IgG4 acts by blocking IgE binding, and thus obviously requires IgE production 
before it has a tolerogenic function (Nouri-Aria et al. 2004, van Neerven et al. 1999, Wachholz 
et al. 2003). The anti-inflammatory mechanism of specific IgA is not fully understood, but it 
does not inhibit IgE binding (van Neerven et al. 1999, Pilette et al. 2007). In mucosal surfaces, 
particularly in the intestinal tract, higher secretory IgA concentrations may more effectively 
inhibit absorption of food allergens. It may thus function even before IgE levels have reached 
levels where inhibition would make a difference. Our data on kinetics of CM specific humoral 
responses as well as on CM epitope binding support this theory. 
 
Balance of T regulatory and T effector cells in CMA and development of 
tolerance   
 
 
Our study shows that the balance of T regs and T effector cells, Th2 in particular, function 
crucially determines whether CMA persists or tolerance develops. We observed that after β-
lactoglobulin stimulation, the combined mRNA expression profile of a Treg-determining 
(FoxP3), a multifaceted T cell-related (Nfat-C2) and a Th2-determining (GATA-3) 
transcription factor, and cytokine IL-16 distinguished three groups from each other: patients 
with persisting CMA, patients who had recovered from CMA and non-atopic children. On the 
antibody level, the increase of specific IgG4 concomitantly with a decrease in specific IgE in 
patients who recovered early further emphasizes the importance of Treg/Th2 balance.  
 
Treg activation among children with CMA, in contrast to non-atopic subjects, was inferred by 
strong FoxP3 intensity in circulating CD4+CD25highCD127low cells and high FoxP3 mRNA 
expression in PBMCs in response to in vitro β-lactoglobulin stimulation. We found no 
difference in the numbers of CD4+CD25highCD127low cells between the study groups. Our 
findings thus contradict the study by Karlsson et al where frequencies of circulating Tregs were 
higher in patients who had recovered from CMA than in patients who remained clinically 
reactive to CM (Karlsson, Rugtveit & Brandtzaeg 2004).  Our results are partly in line with a 
more recent study, which reported that frequency of polyclonal Tregs in peripheral blood did 
not differ between patients with active and recovered cow’s milk allergy, although the latter 
had higher frequencies of antigen-specific Tregs(Shreffler et al. 2009); we did not, however, 






In addition to Treg-related transcription factor FoxP3, the mRNA expression profile 
distinguishing study groups included markers also related to Th2 activation. GATA-3 is widely 
used as a Th2 marker since it is the major transcription factor that induces the expression of 
Th2 polarizing cytokines (Zheng, Flavell 1997, Pai, Truitt & Ho 2004). The interaction of 
those cytokines with FoxP3+  Treg development appears to be inhibitive (Wei et al. 2007).  The 
transcription factor Nfat-C2 has variable functions: it may induce T effector cell activation, or 
initiate anergy, or promote Treg function in interaction with FoxP3 (Wu et al. 2006, Bettelli, 
Dastrange & Oukka 2005, Bopp et al. 2005).  Studies have associated IL-16 with promoting 
either tolerance or allergy. This cytokine induced the migration to inflammation sites of 
CD4+CTLA+ cells, which were enriched in FoxP3 (McFadden et al. 2007). It furthermore 
stimulated FoxP3 expression in the recruited cells (McFadden et al. 2007). In PBMCs from 
patients sensitive to ragweed, IL-16 reduced allergen induced IL-5 and IL-13 expression 
(Pinsonneault et al. 2001, El Bassam et al. 2006).In contrast, atopic dermatitis severity 
correlated positively with IL-16 serum levels (Angelova-Fischer et al. 2006), and clinical 
improvement was associated with decreasing levels both in an observational study (Angelova-
Fischer et al. 2006) and during successful house dust mite specific immunotherapy (Bussmann 
et al. 2007).  
 
Our data on specific antibodies to CM proteins are partly in agreement with the results from 
experiments with PBMCs. In patients with persisting CMA, CM specific IgE levels were 
highest, reflecting Th2 activity. Patients who recovered early had lower specific IgE levels, but 
still even after recovery the levels were higher than in control subjects. Specific IgG4 levels 
were higher in patients who recovered early, and on similar levels in control subjects, 
compared with patients with persisting CMA.  Since IL-10 secreted in particular by Tr1 cells 
promotes B cells to switch from IgE to IgG4 production (Jeannin et al. 1998, Satoguina et al. 
2005, Meiler et al. 2008a), our data implies heightened Tr1 activity in tolerance development. 
When studying PBMCs stimulated with a CM antigen, we showed that Tregs were activated in 
both patients with persisting and recovered CMA. We did not, however, study subpopulations 
of Tregs, and thus Tr1 cells may be more activated in tolerance development than in active 
allergy even if the entire population of Tregs is not. The finding that infants who received CM 
during first days of life and later developed CMA had higher levels of specific IgG4, and thus 
plausibly Treg activity, further underscores that it is the balance of Th2 and Treg activity which 
determines the immunological outcome. 
 
The FoxP3 response to in vitro β-lactoglobulin stimulation in non-atopic subjects was weak 
compared with patients with CMA. The finding implicates that non-allergic long-term 
tolerance relies more on anergy than up-regulation of FoxP3 in Treg activation. It does not 
exclude, however, the possibility that tolerance to CM in non-atopic individuals involves 
activated Tregs in the gut, which is then reflected as unresponsiveness in peripheral blood.  On 
the other hand, a recent study reported higher numbers of FoxP3+ cells in duodenal biopsies 
of patients with food allergy compared with healthy subjects (Westerholm-Ormio et al. 2010). 
Our study showed that PBMCs from patients with CMA responded to CM antigen exposure 





responses since Th2 pathways became activated as well. Our data thus demonstrate that both 
Treg and Th2 pathways are active in allergy, and Treg activation in peripheral blood does not 





We investigated a relatively large number of patients belonging to a population-based cohort of 
6209 infants.  The feeding trial was randomized, controlled and double-blind. The study 
followed prospectively the natural course of CMA up to the median age of 8.6 years. The 
diagnostic criteria were stringent. What is more, for studies III-V we only included patients 
with IgE-mediated CMA, which further strengthened the reliability of CMA diagnoses and the 
comparability of study groups. In studies I-II we stratified the data to IgE- and non-IgE-
mediated CMA when it seemed meaningful.  
 
Our principal aim was to compare, at three time points, patients who recovered by age 3 years 
with patients who had persistent CMA beyond age 8 years. We also had samples of control 
subjects with no history of CM related symptoms from the same original cohort at follow-up 
(median age 8.6 years), but not at earlier time points. These control subjects had been 
meticulously investigated for diverse manifestations of atopy, found to have less atopy than the 
patient population and had been confirmed to be negative in respect to CMA (Saarinen et al. 
2005). The subjects designated as controls in study II had had CM related symptoms that had 
receded during elimination diet. They may thus have had a very transient form of CMA. The 
controlled CM challenge was performed within in average 3 months (mean, SD +/-2) after the 
emergence of CM related symptoms (Saarinen et al. 1999). On the other hand, comparing 
children with CM related symptoms addresses the issues in CMA diagnostics in a clinically 
more realistic setting than comparison with asymptomatic children. 
 
For technical reasons, the specific IgA and IgG4 levels were measured in arbitrary units, and 
values for different antibodies are thus not directly comparable. Another technical weakness 
was that CM epitope binding by IgA was not performed with a dendrimer-amplification 
protocol like that by IgE and IgG4 were. The signal was thus lower and less comparable to the 
one by IgE and IgG4. Studies on epitope binding by IgA in food allergies are rare, and despite 
the technical shortcoming our study provided novel insight on IgA antibodies in CMA.  
 
We screened the five filaggrin mutations that reportedly are the most common in Caucasian 
population (Sandilands et al. 2007). Only one of them was present in our study population. In 
order to claim that no other filaggrin mutations were present, we should have sequenced the 
entire filaggrin gene from all the individuals. A few rare mutations in filaggrin gene reportedly 
do contribute to the risk of atopic dermatitis (Sandilands et al. 2007). Due to constrained 






Our results on IgE epitope recognition did not conform to reports from a few previous 
studies. To our knowledge, the current study was the first to prospectively investigate the 
prognostic value of epitope profiling in CMA at the time of diagnosis: In later time points, the 
explanation for discrepancies may lie in different patient characteristics and in stages when 
CMA was investigated. Our patients were from a prospective study, where patient underwent 
the diagnostic controlled oral CM challenge at mean age 7 months, which was on average 
within only four months after the first symptoms (Saarinen et al. 1999). The relatively low CM 
specific IgE levels in our patients therefore plausibly reflect the short period of CM 
sensitization. CM specific IgE levels were considerably higher and patients had more severe 
symptoms, including anaphylaxis, in previous studies, where patients were recruited at 
specialized referral centers (Vila et al. 2001, Jarvinen et al. 2002), than in the current study. 
Furthermore, we investigated samples from the early (at diagnosis and one year after) and later 
(at mean age 8.6 years) stages of CMA, whereas samples in the afore mentioned studies were 
drawn at school age only (Vila et al. 2001, Jarvinen et al. 2002). Cerecedo and coworkers 
(Cerecedo et al. 2008) investigated patients with CM specific IgE levels more comparable to 
those in the current study. Their cut-off for persistent or transient CMA was, however, much 
lower i.e. median age two years, which implies that many patients categorized to have 
persistent CMA probably became tolerant before school age since the majority of patients do 
(Host, Halken 1990, Saarinen et al. 2005, Skripak et al. 2007). Since patients with CMA have 
the potential of recovery at any age (Skripak et al. 2007), the life-time prognosis of patients 
with CMA categorized as persistent can be expected to differ from study to study. A factor 
that is bound to confound any study on epitope recognition is the observation that individual 
diversity in CM epitope recognition by IgE is considerable (Cocco et al. 2007, Han et al. 2008). 
Differences in methods, sensitivity in particular, and statistical analysis may also contribute to 
the variance between studies. 
 
In study V, the amount of PBMC samples obtained from children were insufficient for 
suppression experiments. We did, however, investigate cell markers which have been shown to 
identify Tregs and those cells to have suppressive function (Liu et al. 2006, Seddiki et al. 2006). 
 
In study III we used a random decision tree method to find a combination of epitope binding 
that would predict the clinical course of CMA. Decision tree methods are strong predictors 
and able to identify interactions between variables. They have indeed been successfully applied 
in several biomedical applications (Kingsford, Salzberg 2008, Reif et al. 2009). However, our 
results need to be tested with another patient population. 
 
We applied artificial neural network analysis in study IV to find an optimal marker 
combination distinguishing the three study groups. This method is able to penetrate the 
complex data and underlying interactions (Krogh 2008, Khan et al. 2001, Lancashire et al. 





the result of the analysis should be validated with another data set that the neural network was 
not trained on (Krogh 2008).  
 
All in all, we are confident that the methodology adequately addressed the aims of the study 
despite some constraints related to the availability of patient samples, technical issues and at 
times limited resources. The underlying strength of our study was the relatively large and well-
characterized study population. 
 
Implications for CMA diagnostics and prognostics 
 
Our results reinforce the role of CM specific IgE levels in diagnostics and prognostics of 
CMA. Our study furthermore suggests that in diagnostics, low levels of specific IgG subclass 
antibodies to CM proteins support a CMA diagnosis. For predicting the natural course of 
CMA, β-lactoglobulin specific IgA may give additional information.  Specific IgG4 levels are 
not as useful since the difference between patients with transient or persistent CMA was 
evident only after the time of diagnosis. Our data corroborate, nevertheless, that both IgA and 
IgG4 subclasses play a role in the development of tolerance in CMA, and may thus serve as 
markers and vehicles worth investigating in immunotherapeutic settings.  
 
CM epitope binding profile of IgE has previously given some hope of becoming a tool in 
CMA prognostics. With random decision tree analysis, we did find some IgE and IgG4 peptide 
recognition patterns that categorized patients with persisting or transient CMA rather 
accurately. The entire peptide microarray data in our study does not however provide a clear 
pattern of epitope binding that would differ at the time of diagnosis between patients who 
recovered early and those whose CMA persisted. The variability of IgE epitope profiles 
between individuals (Cocco et al. 2007, Han et al. 2008)  further complicates the interpretation 
of epitope profiling in clinical practice. Our results thus provide at most weak support for the 
application of epitope profiling in CMA prognostics. Previous studies have not evaluated 
prospectively epitope binding by IgE in patients with different pace of recovery, and they have 
thus extrapolated the retrospective results to have prognostic value. Overall, IgE binding was 
more intense and stable over time in patients with persistent CMA. An advantage of epitope 
profiling with the microarray-based immunoassay is its high sensitivity (Lin et al. 2009). It is, 
however, questionable whether this kind of analysis would substantially add to the basic 
measurement of CM specific IgE levels in clinical practice. Our results on epitope profiling 
rather add to the body of evidence on the role of antibodies in tolerance and active allergy, 
than provides insights for clinical applications. 
 
Our study did not return genetic associations with CMA, and thus we cannot recommend 





responses to early oral antigens were associated with HLA haplotypes. Further research on the 
matter may provide clinical applications that could assist in managing the risk and clinical 
course of CMA. 
 
We found a combination of gene expression markers that distinguished patients with persisting 
or recovered CMA or non-atopic subjects. The categorization was, however, performed 
retrospectively. A prospective study must be carried out before the value of T cell profiling in 
CMA prognostics can be evaluated. Our findings do clearly point out that the frequency or 
activity of Tregs is not a reliable indication of tolerance in CMA. 
 
In conclusion, specific IgE, IgG4 and IgA antibodies to CM proteins appear to provide useful 
and complementary information on the immunological status and reflect the clinical activity in 
CMA. In the development of novel clinical applications for CMA diagnostics and prognostics, 





Summary and conclusions 
 
Our study confirms that specific IgG subclass, especially IgG4, play a role in the induction and 
maintenance of tolerance. Also specific IgA appears to promote tolerance. Our results 
corroborate that high CM specific IgE levels predict the persistence of CMA. A more novel 
finding was that specific IgA levels at the time of diagnosis may also have prognostic value. 
Data from studies on specific antibodies to whole CM proteins and from CM epitope profiling 
were largely in agreement with each other. CM epitope binding by IgE and IgG4, but not IgA, 
overlapped, which suggests that IgG4 acts by blocking IgE whereas IgA induces tolerance 
through another kind of mechanism.  
 
Our results propose that the risk of CMA cannot be assessed with HLA II genotyping. 
Intriguingly, HLA II genotype modulates, however, the humoral response to CM proteins.  
The specific humoral response is overall upregulated upon early exposure to CM in the context 
of sensitization, where tolerogenic IgG4 fails to surpass the effect of allergenic IgE.   
 
Profiling of gene expression markers further emphasized the importance of the balance 
between Th2 and Treg activity. Expression data on both mRNA and protein level 
demonstrated that Treg activation upon CM antigen stimulation is stronger in patients with 
CMA than in non-atopic children. Contrary to the current paradigm, Treg function in 
peripheral blood appears to be active in allergy and less so in the maintenance of long-term 
oral tolerance, which plausibly relies on other immunological mechanisms such as T cell 
anergy. 
 
We investigated the immunological mechanisms behind the emergence and persistence of 
CMA and the induction of oral tolerance. Our study revealed several phenomena which could 
be translated into clinical prognostics and immunotherapy in CMA. Validating our results 
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